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1 INTRODUCTION
The largest organ in the human body is the skin, which produces a vital barrier between the
environment and human tissues and body fluids. The most important contribution to the barrier
function comes from the uppermost layer of the epidermis, the cornified cell layer. This layer forms
envelope networks, a lipid envelope and a protein envelope, which are impermeable structures keeping
harmful organisms outside and important agents inside the body. The importance of this barrier
function is demonstrated by an inherited defect of barrier function observed in certain scaling diseases
of the skin, known as the ichthyoses. For newborns, these are life-threatening conditions involving the
loss of body fluids and risk of sepsis.
Ichthyoses form a heterogeneous group of diseases or syndromes, connected by defective keratinization
and scaling of skin. Ichthyotic diseases have a long history; the earliest observation is described in 250
BC in an Indian text as “Ekakushtha, skin disease like scales of fish” (Menon and Hoberman 1969). It
was not until the 1900s when the classification of ichthyoses became clearer after separation of X-
linked ichthyosis, ichthyosis vulgaris, lamellar ichthyosis, and syndromic variants in 1950-1970
(Griffiths et al. 1998). The first ichthyosis described biochemically was X-linked ichthyosis, when the
steroid sulphatase deficiency was discovered in patients with X-linked ichthyosis (Shapiro et al. 1978).
The development of modern technologies in molecular genetics has revolutionized the study of
inherited diseases such as ichthyoses. Breakthroughs emerging from clinical studies in study of the
pathogenesis of ichthyoses during the last decade have revealed involvement of at least eight different
known genes and three different chromosomal loci in the pathogenesis of different forms of ichthyoses
and ichthyosiform syndromes. Specifically, these studies have illuminated the importance of keratins,
lipid metabolism, and the cornified cell envelope for normal function of the skin. The genetic
heterogeneity underlying the ichthyoses has been surprisingly large: for example, in autosomal
recessive ichthyosis alone at least five (and probably more) different genes underlie the disorder.
Despite considerable progress within the field, the pathogenesis of about 10 ichthyotic diseases or
syndromes remains unknown.
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2 REVIEW OF THE LITERATURE
2.1 EPIDERMAL DIFFERENTIATION
2.1.1 The program of terminal differentiation
The epidermis is a continuously renewing tissue, comprised of four histologically distinct cellular
layers (the basal layer, the spinous layer, the granular layer, and the cornified layer), each with a distinct
maturation state of the keratinocyte (Figure 1). Keratinocytes arise from stem cells in the basal layer of
the epidermis and in the bulge region of the hair bulb (reviewed by Hall and Watt 1989), and move
through a series of differentiation events until they are finally sloughed into the environment
(desquamation) (reviewed by Eckert et al. 1997). In the normal epidermis, a balance exist between the
process of proliferation and desquamation that results in its complete renewal approximately every 28
days. (Roop 1995).
The basal epidermal layer consists of a single layer of relatively undifferentiated cells that are anchored
to the basal lamina via hemidesmosomal junctions (Borradori and Sonnenberg 1996). Two types of
proliferative keratinocytes have been found in the basal layer: 1) The stem cell, which has a high self-
renewal capacity and low probability of terminal differentiation and expresses a high amount of β1
integrins, 2) The transit-amplifying cell, the daughter of a stem cell that is destined to differentiate
within about three to five rounds of division (Zhu et al. 1999). A typical feature of basal cells is to
express keratins 5 (K5) and 14 (K14) (Steinert 1993). Impelled by some as-yet-unidentified trigger(s) of
terminal differentiation basal cells will begin their journey to the skin surface. As basal cells
differentiate they downregulate the expression of K5/K14 and induce expression of keratins 1 and 10,
and later also keratin 2. In palmar and plantar skin additional keratins, keratins 6a, 6b, 9, 16, and 17 are
expressed (Fuchs 1993).
In the later stages of terminal differentiation the expression of a number of proteins is activated. One of
them is profilaggrin, a histidine-rich basic protein, which is proteolytically processed into filaggrin
monomers. Filaggrin functions as an intermediate filament-associated protein that aggregates keratin
filaments in cornified cells (Ishida-Yamamoto et al. 1999). Lamellar granules, produced earlier, fuse
with the plasma membrane and release lipids into the intercellular spaces of granular and stratum
corneum cells. An important step in terminal differentiation is the formation of the cornified cell
envelope (CE), a structure which consists of a lipid and protein envelope and forms an impermeable
barrier in the cell. The earliest CE protein to be expressed is involucrin in the upper spinous layers,
followed by expression of later differentiation proteins such as loricrin (Fuchs 1993; Rossi et al. 1998).
The end-product of terminal differentiation is the corneocyte, a flattened cell whose organelles have
broken down and which is metabolically inactive. A corneocyte consists simply of a keratin filament
matrix embedded in a filaggrin matrix and encased by a cornified cell envelope. The extracellular
matrix is replaced by lipid lamellae, and together the CE and lipids form an impermeable barrier against
the environment. Finally, the corneocytes peel off from the skin as dead debris (Eckert et al. 1997). The
pathway of epidermal differentiation is presented in Figure 1.
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Figure 1. Morphological progression of
keratinocytes during differentiation with
epidermal layers on the left, as well as
cell organelles and certain molecules
involved in non-syndromic geno-
dermatoses. Corresponding geno-
dermatoses are shown on the right.
Abbreviations: ARCI, autosomal
recessive congenital ichthyosis; ATP2A2
and ATP2C1, Ca2+ transporting ATPase
2A2 and 2C1; BIE, bullous
ichthyosiform erythroderma; BPAG2,
bullous pemphigoid antigen 2; EB,
epidermolysis bullosa; ED/SF srd,
ectodermal dysplasia/skin fragility
syndrome; EKV, erythrokeratodermia
variabilis; GJB2 and 3, gap junction
protein beta 2 and 3; HL, hearing loss;
IBS, ichthyosis bullosa of Siemens; K,
keratin; NEPPK, non-epidermolytic
palmoplantar keratoderma; PC 1 and 2,
pachonychia congenita 1 and 2; PPK,
palmoplantar keratoderma; PPK+HL,
palmoplantar keratoderma + hearing
loss; PSEK, progressive symmetric
erythrokeratoderma; SPPK, striate
palmoplantar keratoderma; SPRs, small
proline rich proteins (Adapted and
reproduced with permission from Roop,
D. (1995), Science 267:474-475).
2.1.2 Regulation of epidermal differentiation
Factors that trigger epidermal cell commitment and differentiation are still incompletely understood,
although specific factors have been identified that regulate keratinocyte proliferation and
differentiation.
Calcium belongs to a group of important regulatory factors of the skin. A calcium gradient is known to
be present in the epidermis, such that the calcium content is fourfold higher in the superficial than in
the basal epidermis (Eckert et al. 1997). Calcium-dependent processes include a number of cellular
events such as the activation of enzymes, for example transglutaminase 1 (TGase 1), the secretion of
lamellar bodies, desmosome formation, and cell adhesion (Vicanová et al. 1998). Recently, two
inherited skin diseases, Darier-White disease (OMIM 124200) and Hailey-Hailey disease (Benign
chronic pemphigus) (OMIM 169600, were shown to be associated with defects in calcium pumps
expressed in the skin (Hu et al. 2000; Sakuntabhai et al. 1999). Sarcoendoplasmic reticulum Ca2+
ATPase ATP2A2 (SERCA2) was shown to be the cause of the Darier-White disease, whereas
mutations in ATP2C1, which in yeast pumps Ca2+ from cytoplasm to the Golgi, were found in Hailey-
Hailey disease. These two diseases further provide evidence for the importance of the Ca2+ signaling
pathway in the skin.
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Retinoids (vitamin A and related agents) are potent modulators of keratinocyte differentiation (
reviewed by Fisher and Voorhees 1996). In keratinocytes, retinoids bind to retinoid receptors (RARs
and RXRs) which activate gene expression by interaction with DNA response elements located near
responsive genes or by interacting with other transcription factors. The effects of retinoic acid in the
epidermis in vivo and in vitro differ. In cultured keratinocytes, retinoids inhibit terminal differentiation
(Jetten 1990), which is manifested by decreased expression of differentiation-associated keratins 1 and
10 (Fuchs and Green 1981), filaggrin (Asselineau et al. 1990) and cell-envelope proteins (Griffiths et al.
1992; Hohl et al. 1991; Magnaldo et al. 1992; Marvin et al. 1992; Yuspa and Harris 1974). In vivo,
retinoids stimulate keratinocyte proliferation and growth, and no suppression of terminal differentiation
is observed (Fisher et al. 1991). Differences of in vivo and in vitro responses to retinoids have been
suggested to depend on the absence of other signals, including the influence of the important dermal
signal, which is not present in culture (Aaronson et al. 1991; Tavakkol et al. 1992). The complexity of
retinoid metabolism in the skin is emphasized by the fact that pathogenic thickening in many skin
diseases is ameliorated with retinoids.
Many other effectors such as transforming growth factor B, keratinocyte growth factor, interferon γ, and
vitamin D are also known to affect epidermal differentiation (Eckert et al. 1997). However, each marker
has its own peculiar regulatory features and each marker form a complex network of signals.
Elucidation of these networks and their role in epidermal differentiation remains to be determined
(Mariniello et al. 1995).
2.1.3 Cornified cell envelope
The cornified cell envelope (CE) is a 15 to 20-nm-thick structure formed on the inner surface of the cell
membrane by aggregation of a series of proteins that are cross-linked together both by disulfide bonds
and by the Nε-(γ-glutamyl)lysine isopeptide crosslinks. Transglutaminases (Tgases) catalyze the
formation of cross-links in CE (Figure 2) (Steinert 1995). The CE is a highly insoluble protein complex
constituting about 10% of the mass of a terminally differentiated corneocyte. CE consists of two parts:
a protein envelope and a lipid envelope. The lipid envelope is located on the exterior of the protein
envelope and consists of a monomolecular layer of ω-hydroxyceramides attached to the protein
envelope by ester bonds. ω-hydroxyceramides provide a Teflon-like coating to the cell and also
interdigitate with the intercellular lipid lamellae (Nemes and Steinert 1999).
The CE is a common feature of all stratified squamous epithelia of various species, although between
epithelia its precise composition and structure vary widely. It is unclear when the assembly of the CE
begins in the epidermis, but evidence suggests that the assembly is a multi-stage process. Recent
immunogold-labeling and protein-sequencing data suggest that the most critical components of the
earliest stages of CE formation are involucrin and perhaps also putative membrane-anchoring proteins
such as envoplakin and periplakin (Steinert and Marekov 1999). When the local Ca2+ concentration
rises during the epidermal differentiation, TGase 1 starts cross-linking involucrin polymers and
possibly envoplakin and periplakin at the interdesmosomal region to form a scaffold for the CE (Nemes
et al. 1999). Involucrin has also been shown to attach to ω-hydroxyceramides via ester-bond formation
catalyzed by TGase 1 (Nemes et al. 1999). This process is continued by the attachment of other CE
proteins, such as cystatin A, to the involucrin network. This layer serves as a substrate for deposition of
loricrin together with other proteins. Loricrin is the major protein of nearly all CEs characterized to
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date, accounting for approximately 60 to 80% of the protein mass of the CE. (Jarnik et al. 1998; Steven
and Steinert 1994). Small proline-rich proteins are suggested to function as stabilizers of CE-forming
cross-links between loricrin and other CE substrates in reactions catalyzed by both TGase 1 and 3
(Candi et al. 1999).
Figure 2. Model of the structure of the cornified cell envelope. The cytoplasmic surface of the protein envelope consists
mostly of loricrin admixed with many other proteins; the surface facing the lipid envelope consists of other structural
proteins such as envoplakin, involucrin, and desmoplakin. The keratin cytoskeleton is suggested to associate in two ways
with CE (Adapted and reproduced with permission from Steinert, P. (1998), J Biol Chem 273:11758-11769).
2.2 TRANSGLUTAMINASES
Transglutaminases (Tgases for protein, TGM for gene) represent a family of enzymes capable of
stabilizing protein assemblies via γ-glutamyl-ε-lysine cross-links (reviewed by Aeschlimann and
Paulsson 1994; Greenberg et al. 1991). Enzymes of this family catalyze Ca2+ -dependent transfer
reactions between the γ-carboxamide group of a peptide-bound glutamine residue and various primary
amines, most commonly the ε-amino group of lysine residues (Figure 3). It appears that nature has not
provided an enzyme for the cleavage of the TGase cross-link. Therefore the action of these enzymes
results in the formation of irreversibly cross-linked, often insoluble molecular structures. Seven
different TGM gene products with amino acid homology of 20 to 40% have been characterized in the
human genome thus far by determination of their primary structures (Table 1). Furthermore, secondary
structure predictions show even greater degrees of structural conservation (60-70%).
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Figure 3. Simplified model of transglutaminase catalyzed formation of the isopeptide bond.
A) TGase 1 (TG, open circle) is inactive in the absence of calcium and is anchored to the
plasma membrane. Glutamine substrate is shown in the cytoplasm as solid rod. B) In the
presence of calcium, TGase 1 is activated (shaded circle) and forms an enzyme-substrate
intermediate with the glutamine substrate with a concomitant release of ammonia. C) The
intermediate then reacts with the lysyl substrate (primary amin donator) to form a cross-link
D) The completed cross-link is shown (Adapted and reproduced with permission from
Eckert, R. (1993), J Invest Dermatol 273:11758-11769).
TGases appear early in evolution, and enzymes with similar function to vertebrate TGases have been
detected in invertebrates, plants, and bacteria, actually in all organisms studied (Polakowska et al.
1999). Considering the rates of divergence of the TGM genes between different species, it is likely that
vertebrate TGM were distinct from each other before reptiles separated from fish about 400 million
years ago (Aeschlimann and Paulsson 1994). Two evolutionarily different lineages in human beings
have been suggested on the basis of homology: 1) TGase 2, 3 and band 4.2, and 2) TGase 1 and FXIII.
In plants TGases have been found from pollen and chloroplast, suggesting the role in fertilization and
light capture (Del Duca et al. 1994) (Del Duca et al. 1997). TGases could also have an interesting
industrial applications in pharmaceutical and food industry as a biological glue and for cross-linking
food proteins (Jurgensen et al. 1997; Matheis and Whitaker 1987).
2.2.1 Function of transglutaminases in keratinocytes
During different stages of epidermal differentiation four TGases are expressed. TGase 2 is expressed
primarily in the basal cell layer early in epidermal differentiation. The function of TGase 2 in
keratinocytes is unclear, but it has been suggested to play a role in stabilization of the dermo-epidermal
junction. (Kim et al. 1995; Raghunath et al. 1996). TGase 1 and 3 are associated with terminal
differentiation events of keratinocytes and cross-linking the structural proteins forming the cornified
cell envelope, but they act in different ways. The major part of TGase activity in the suprabasal cells
comes from TGase 1, whereas the expression of TGase 3 in those cells is relatively low. Although the
details of CE formation by TGases are still unclear, it has been speculated that TGase 1 forms the major
scaffold of the CE and that TGase 3 strengthens the structure (Kim et al. 1995). TGase X is a recently
discoverd, novel transglutaminase, which is expressed in terminally differentiating keratinocytes and
whose function in skin is still unknown (Aeschlimann et al. 1998). Based on their spatial and temporal
expression and functional significance, the family of TGases are strong candidates for disorders of
epidermal differentiation and cornification.
17
Table 1 Human transglutaminases
Name Synonym Symbol Tissue
expression
Physiological role Diseases Amino acid
homol. to
TGM 1
Gene
size
Chrom.
locus
Protein size
Transglut-
aminase 1
Keratinocyte
transglutaminase
TGase 1,
TgK
epidermis,
epithelia,
brain,
Formation of CE ARCI
AD?
100% 14 kb 14q11.2-13 106 kDa
67/33/10 kDa
Transglut-
aminase 2
Tissue
transglutaminase
TGase 2,
TgC
ubiquitous Apoptosis, GTP-binding
and signaling, stabilizing
extracellular protein
assemblies
CD1,
AD2?,
PD3?,
TED4?
36% unknown 20q11.2 77 kDa
Transglut-
aminase 3
Epidermal
transglutaminase
TGase 3,
TgE
epidermis, hair
follicle
Formation of CE, hair
formation
no
association
37% 43 kb 20q11.2 77 kDa
Transglut-
aminase 4
Prostate
transglutaminase
TGase 4,
TgP
prostate unknown no
association
35% 35 kb 3p21.33-
p22
77 kDa
Transglut-
aminase 5
4.2 Band protein TGase 5 erythrocytes Cytoskeleton component no
association
27% 20 kb 15q15
Transglut-
aminase 6
Coagulation factor
XIII a subunit
FXIII platelets,
macrophages,
monocytes,
megakaryocyte
uterus, placenta
(dimeric),
plasma
(tetrameric)
Cross-linking of fibrin
network in blood
coagulation
Bleeding
disorder
FXIII
deficiency
43% 160 kb 6p24-25 83 kDa
Transglut-
aminase 7
transglutaminase X TGase 7 keratinocytes unknown no
association
35% unknown unknown 81 kDa
1 CD (Celiac disease)
2 AD (Alzhermer disease)
3 PD (Parkinson disease)
4 TED (Trinucleotide expansion diseases)
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2.2.2 Transglutaminase 1
2.2.2.1 Gene
The gene transglutaminase 1 (TGM 1), coding for TGase 1, has been localized to chromosome
14q11.2-13. (Kim et al. 1992). It is the smallest gene in the TGM family, spanning about 14 kb of
genomic DNA. The TGM 1 gene, which exists as a single copy in the human genome, consists of 15
exons interrupted by 14 introns. Sequences of both exon and intron regions are known and two
sequence variants for TGM 1 in the human population have been noted. The rare smaller variant, with a
frequency of approximately 4%, contains a two-nucleotide deletion near the 5’ end, uses an alternate
initiation codon, and differs from the common larger variant only in its first 15 amino acids. Intron 14
of the TGM 1 gene contains a polymorphic dinucleotide area useful for genetic linkage analysis.
Rodent and human TGM 1 gene sequences are highly conserved: 84% sequence identity and 92%
amino acid identity between human and rat exist. (Phillips et al. 1992).
The molecular mechanisms that control the transcription of the TGM 1 gene are poorly understood, but
some data reveal transcription regulatory elements of the TGM 1 gene. Two transcription control
elements are suggested to regulate the TGM 1 gene: a proximal promoter in the 5’region and a
transcription regulatory element in intron 1. Functional mapping of deletion mutations in regulatory
elements of the TGM 1 5’upstream promoter region and intron 1 demonstrated that maximal activity of
reporter enzyme activity was achieved when both elements were present. The proximal 5’region
contains four different types of regulatory elements: 1) three AP2-like response elements conserved
also in the rabbit TGM 1 promoter region, 2) two AP1 sites, 3) SP1 site, and 4) direct repeat 5 (DR5)
type of retinoid acid response element (RARE) mediating retinoid adic-receptor (RAR) signaling. The
5’region also contains two sub-elements silencing and enhancing Ca signaling. Intron 1 is suggested to
contain two major sites important to transcription of TGM 1: 1) the negative element containing a
reverse CCAAT box and a short RARE element and 2) a 194 bp element, which may function under
unidentified conditions as an alternative promoter. In addition, intron 1 contains SP1, AP1, and AP2
sites similar to those found in the 5’region. The precise regulatory role of all these elements is still
unclear (Polakowska et al. 1999).
2.2.2.2 Structure
The only TGase for which the three-dimensional structure is known is the A subunit of FXIII. Because
of significant amino acid homology (43%), TGase 1 is suggested to share the same three-dimensional
structure (Figure 4). This structure consists of four sequential domains; the β-sandwich, the catalytic
core domain, and the β-barrel domains 1 and 2. The secondary structure of the core domain is a mixture
of α-helix and β-sheet, whereas the remaining three domains consist predominantly of β-sheet (Yee et
al. 1994). The highest degree of homology is exhibited in the catalytic core domain, which contains the
three conserved catalytic triad residues: Cys376, His432, and Asp456. Most of the structural
differences between FXIII and TGase 1 are in the C- and N-terminal regions. The N-terminus in TGase
1 contains a membrane anchor region, whereas in FXIII this area contains the activation peptide, which
is cleaved by thrombin in the coagulation cascade leading to activation of FXIII. However, recent data
suggest that TGase 1 is also proteolytically processed at Arg 92, a region corresponding to the thrombin
cleavage site in FXIII (Candi et al. 1998). Accordingly, it has been suggested, although no structural
data are available, that the membrane anchorage region of
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Figure 4. Stereoviews showing amino acid residues conserved in human TGase 1
and blood coagulation factor XIII A-subunit. The three-dimensional structure of
the factor XIII A-subunit is shown as a coil structure, with the N- and C- termini
and four domains labeled. Thick dark lines connecting alpha carbon atoms are the
three regions which are sites of amino acid deletions in TGase 1 relative to factor
XIII. Superimposed on the coil structure are the side chain moieties of amino acid
residues conserved in human TGM 1 and factor XIII sequences (299 residues,
42%). The high level of sequence conservation, and the distribution of conserved
residues throughout indicate that the factor XIII A-subunit and TGase 1 possess
the same protein fold. (Courtesy from Dr. Vivien Yee, Cleveland Clinic
Foundation, Ohio).
TGase 1 may fold onto the body of the TGase 1 enzyme, like activation peptide in FXIII, to partially
obstruct access to the active site.
2.2.2.3 Expression and tissue distribution
In human epidermis, TGM 1 is first expressed in fetal periderm cells at the stage of the appearance of a
two-layered epidermis (appears at 7-10 weeks of gestation) and later in the entire epidermis, although
the expression is strongest in the upper epidermis (Akiyama et al. 1999; Lee et al. 1999). In mature
human epidermis, TGM 1 expression is detected in minor quantities in the proliferative basal layer, in
modest amounts in the suprabasal cells committed to differentiation, and then in much larger amounts
in the granular layer as terminal differentiation in the epidermis and cornified cell assembly proceeds
(Steinert et al. 1996). There are controversial results surrounding the expression of TGM 1 in epidermal
appendages, depending on the antibody used. The goat polyclonal anti-TGase 1 antibody reveals its
expression in hair follicle, sebaceous, and sweat glands, whereas the mouse monoclonal B.C1 antibody
does not stain sebaceous glands (Yoneda et al. 1998). TGase 1 expression is also detected in other
epithelial tissues that do not keratinize, such as oral-cavity, esophagus, trachea, lung, liver, and intestine
(Bradway et al. 1992; Chang and Chung 1986; Hiiragi et al. 1999; Saunders et al. 1993). Recent data
also suggests expression in brain and increased expression and cross-linking in Alzheimers disease
(Kim et al. 1999).
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Endogenous expression of TGM 1 can be regulated by physiological and pharmacological effectors
such as calcium, retinoids, and glucocorticoids. Protein kinase C agonists produce a dramatic
stimulation of expression in primary cultures of keratinocytes. Retinoid acid treatment suppresses its
expression in culture; however, a hyperplastic response increasing expression appears to dominate in
vivo. (Mariniello et al. 1995)
2.2.2.4 Protein function
The TGase 1 enzyme is involved in the formation of a cornified cell envelope in terminally
differentiating, stratified squamous epithelia by cross-linking a series of defined structural proteins. As
mentioned earlier, TGase 1 catalyzes two kinds of reactions in epidermis: formation of χ-glutamyl-ε-
lysine cross-links (see Figure 3) and formation of ester bonds between ω-hydroxyceramides and
involucrin (see Figure 5) (Nemes et al. 1999).
Figure 5. Model of the ester bond formation of TGase 1 and epidermal ceramides. The TGase 1 (solid circle)
and involucrin (solid ovoid) are bound to cellular membrane in the presence of calcium (left). TGase 1 and
involucrin forms an acyl-enzyme intermediate which is exposed to the ω-hydroxyl group of ceramide (center).
Exposing of intermediate to ω-hydroxyl group results in high likelihood of the attack of the hydroxyl group to
intermediatede. TGase 1 is released and ester bond is formed (right) (Adapted and reproduced with permission
from Nemes, Z. (1999), Proc Natl Acad Sci 96: 8402-8407).
TGase 1 exists in epidermal keratinocytes in several forms that are differentially partitioned between
the cytosol and membranes (Steinert et al. 1996). The cytosolic enzyme exists as a full-length form of
106 kDa with low specific activity, and two proteolytically processed forms that have 5- to 10 fold
higher specific activities, one of 67 kDa and a second consisting of 33 kDa fragments held together by
non-covalent bonds (Kim et al. 1995). Together, these three forms constitute from between 5 and 35 %
of the total TGase 1 enzyme activity in proliferating or terminally differentiating cells. The membrane-
bound enzyme exists in two forms: a full-length essentially inactive zymogen; or a complex of
67/33/10 kD chains that is highly active. The proteolytic cleavage at Arg 92 in terminally
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differentiating keratinocytes leads to the formation of the 67/33/10 kDa highly active form showing a
200-fold increase in specific activity (Candi et al. 1998). The membrane-bound zymogen form
constitutes the bulk of TGase 1 protein in keratinocytes. Most of the TGase 1 expressed during terminal
differentiation remains as the full-length inactive membrane-bound form, but up to half of it may be
proteolytically processed into the highly active 67/33/10 kDa form while still anchored to the
membranes.
The TGase 1 enzyme activity is partitioned between the cellular membrane and cytosol compartments
during proliferation and differentiation by the addition of lipid acyl adducts (see Figure 6) (Steinert et
al. 1996). All forms of TGase 1 are N-myristoylated at a cluster of five cystein residues located on the
amino-terminal peptide, which is unique to the TGase 1 enzyme. However, in proliferating and
differentiating cells, the TGase 1 is differentially S-myristoylated or S-palmitoylated, which appears to
confer differing degrees of attachment and provide a variable mechanism for cycling on or off
membranes.
Figure 6. Model of TGase 1 processing and cycling in
cultured keratinocytes. A) All membrane-bound or cytosolic
forms of intact TGase 1 are constitutively labeled by an N-
acyl myristate linkage on glycine residue 3, probably during
or immediately after translation. In proliferating cultures, the
TGase 1 is also thio-esterified. This ”triple-barreled”
labeling affords a more robust anchorage to the membranes
and may serve as a more stable storage form of the zymogen.
Because the half-life of this S-myristoylated label is 18h,
less than for the protein itself, it may provide a novel
mechanism by which TGase 1 can cycle off membranes. B)
During terminal differentiation a much larger amount of
TGase 1 is expressed, all of which becomes N-
myristoylated. After initiation of the differentiation signal,
this newly synthesized protein is also palmitoylated. The
”double-barreled” TGase 1 is less firmly attached to the
membranes, since the half-life of S-palmitate is much less
than the protein’s allowing for a much larger rate of cycling
off membranes (Adapted and reproduced with permission
from Steinert, P. (1996), J Biol Chem 271:26242-26250).
2.2.2.5 Substrates
By in vitro cross-linking studies, TGase 1 has been found to cross-link a number of proteins involved in
the formation of the cornified cell envelope (Candi et al. 1995; Candi et al. 1999; Nemes et al. 1999;
Simon and Green 1988). These proteins also show glutamyl-lysine isodipeptide bonds catalyzed by
TGase when extracted from the CE in vivo. One of these proteins is involucrin (reviewed by Eckert et
al. 1993), which has been assumed to be the major initial component of the CE, forming a scaffold onto
which other proteins are incorporated (Nemes et al. 1999). Recent data also show that involucrin is the
major target for the attachment of ceramide lipids on the exterior surface of the CE (Marekov and
Steinert 1998). Involucrin is a rod-shaped protein of 68 kD rich in glutamine/glutamic acid consisting
of three domains, having an ideal shape for cross-bridging with a variety of molecules (Yaffe et al.
1992). It is expressed by most, if not all, stratified squamous epithelia and is thought to be a ubiquitous
member of the CE (Eckert et al. 1993). In the epidermis, its expression is strongest in the cornified
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layer, but suprabasal cells also show expression in the cell periphery (Rice and Green 1979). However,
not all involucrin protein is incorporated into the CE, and it is possible that other biological functions
of involucrin may exist in the cytoplasm.
Loricrin is a glycine-, serine-, and cysteine-rich, highly insoluble protein expressed in the superficial
granular cells of the epidermis (Mehrel et al. 1990). Loricrin contains repeats of a unique, highly
flexible structure referred to as a ”glycine loop.” Three glycine-rich domains are interrupted with
glutamine-rich domains (Hohl et al. 1991). Loricrin is the major component of the epidermal CE,
constituting as much as 70% of the mass of CE (Steven and Steinert 1994). It is a substrate of TGase 1,
2, and 3 in vitro (Candi et al. 1995). The predominant reaction of TGase 1 is in establishing inter-
molecular cross-links to form very large loricrin oligomers, whereas most of the cross-links formed by
TGase 3 involve intra-molecular cross-links. The preferential Gln/Lys residues used for cross-linkage
differ between TGase 1 and TGase 3, suggesting distinct and perhaps complementary functions of the
two TGases (Candi et al. 1995). Recently, loricrin has been detected as a defective gene in certain
subtypes of two genodermatoses: Vohwinkel’s syndrome (OMIM 604117) and progressive symmetric
erythrokeratoderma (OMIM 602036) (Ishida-Yamamoto et al. 1997; Korge et al. 1997; Maestrini et al.
1996).
Small proline-rich proteins (SPRs) (cornifins, pancornulins) are rather small (10-30 kDa) and rich in
proline, consisting of three domains (Kartasova and van de Putte 1988; Kartasova et al. 1988). The
central domain contains a variable number of repeat elements and is flanked by glutamine- and lysine-
rich terminal domains homologous to the corresponding terminal domains in loricrin and involucrin.
Three types of SPRs exist in humans, forming a complex family of proteins: SPRs 1 (two members),
SPRs 2 (seven members) and SPRs 3 (one member) (Gibbs et al. 1993). Their composition in different
CEs varies widely. In normal human epidermis, SPR 1a is expressed mainly in skin appendages, SPR2
is found in the granular layer, but SPR3 is absent (Hohl et al. 1995). Cross-linking of SPRs occurs at
the amino- and carboxyl-terminal regions, suggesting that SPRs may function as molecular cross-
bridges to connect two proteins. SPRs are substrates for both TGase 1 and 3, but these enzymes cross-
link SPRs in different ways. TGase 3 is suggested first to form small interchain polymers between
loricrin and SPRs1, and further oligomerization then occurs via TGase 1. SPRs2 are mainly cross-
linked by TGase 3 (Candi et al. 1999; Tarcsa et al. 1998).
2.2.2.6 Animal models of the transglutaminase 1 and the cornified cell envelope
Animal models, especially mouse models, have brought interesting insights into the field of TGase 1
and the cornified cell envelope. For example, TGM 1 newborn knock-out mouse have erythematous
skin with coarse wrinkles, and are smaller than their normal littermates. Their skin barrier function is
markedly impaired, and these mice die within 4 to 5 h after birth (Matsuki et al. 1998). Overexpression
of human involucrin in transgenic mice results in scaling and abnormal hair (Crish et al. 1993).
Unexpectedly, in mice, disturbances of the expression of the major structural gene of CE, loricrin, have
relatively minor effects on their clinical phenotype. Transgenic mice overexpressing the loricrin gene,
and mice in whom the loricrin gene has been knocked out, have apparently normal phenotypes,
although the latter exhibit transient neonatal erythroderma (Korge et al. 1997; Yoneda and Steinert
1993). However, transgenic mice with 1 bp (C) insertion at 1190 in the loricrin gene ( Vohwinkel
syndrome mutation) show neonatal erythroderma, impaired barrier function, a marked parakeratosis,
and a constricting band encircling the tail (Suga et al 1999).
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2.3 ICHTHYOSES
2.3.1 Classification of ichthyoses
Ichthyosis describes dry, rough skin with persistent, visible scaling over the body that may resemble
fish scales (ichthys means fish in the Greek). Several different forms exist, and together they comprise a
heterogeneous group of diseases. The clinical diversity of ichthyoses and the rarity of some of them has
lead to a confusing array of classifications over the past century. According to the Textbook of
Dermatology the major types of ichthyoses are congenital ichthyoses, ichthyosiform syndromes and
acquired ichthyoses. Inherited forms of ichthyoses are presented in Table 1 (Griffiths et al. 1998).
Inherited or acquired ichthyoses lead to pathological conditions ranging from fairly mild disease to
lethal conditions. Although inherited ichthyoses are quite rare as causes of human diseases, the study of
rare genodermatoses had provided a powerful tool for understanding the function of skin on a detailed
molecular level, thus opening a whole new set of possibilities for developing diagnostic and therapeutic
tools against ichthyotic disorders. The following two sections introduce the major primary ichthyoses
and ichthyosiform syndromes with their known gene defects.
2.3.2 Major primary ichthyoses
2.3.2.1 X-linked ichthyosis
The first ichthyotic disorder with an established molecular basis was X-linked ichthyosis (OMIM
308100). This was first recognized as a separate disorder in 1933 (Cockayne 1933) and was
differentiated from ichthyosis vulgaris in 1966 (Wells and Kerr 1966). Only males are affected, while
female carriers are asymptomatic. Scaling usually becomes evident at birth or during the first year of
life and is more prominent on the extremities. A variety of extracutaneous features affecting the
genitalia and eyes have been noted (Lykkesfeldt et al. 1985; Lykkesfeldt et al. 1983; Traupe and Happle
1983). Steroid sulphatase deficiency was noted in association with the disease as early as 1978
(Marinkovic-Ilsen et al. 1978; Webster et al. 1978). The first mutations in the steroid sulphatase gene
(STS) were characterized in 1987 by (Yen et al. 1987). Over 90% of patients with STS defect have a
complete or partial deletion of the STS gene. The substrate of steroid sulphatase, cholesterol 3-sulphate,
is elevated in many tissues including the epidermis, where it accounts for 12 to 30% of stratum
corneum lipids in X-linked ichthyosis instead of the 3% in normal skin (Elias et al. 1984). This disturbs
the normal lipid balance within the epidermis. Cholesterol 3-sulphate is also suggested to disturb
TGase 1 function and therefore the normal assembly of the CE (Nemes et al. 2000).
2.3.2.2 Ichthyosis vulgaris
Ichthyosis vulgaris (OMIM 146700) is the most common form of the inherited ichthyosis with a
reported incidence of 1:250 (Wells and Kerr 1966). It is an autosomal dominant condition, and in the
majority of affected individuals the phenotype is relatively mild. A close association between ichthyosis
vulgaris and atopic diseases has been suggested, 37 to 50% of patients with ichthyosis vulgaris showing
features of atopic dermatitis (Fartasch et al. 1989; Kuokkanen 1969; Wells and Kerr 1966). Although
the molecular mechanism of ichthyosis vulgaris is unclear, abnormalities in filaggrin metabolism has
been suggested (Nirunsuksiri et al. 1998; Sybert et al. 1985). Recently, a preliminary linkage study of
one ichthyosis vulgaris family with five affected mapped a suggestive disease locus to the epidermal
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differentiation complex on chromosome 1q21. However, sequencing of the profilaggrin gene located on
this region failed to reveal any mutation (Compton et al. 1998).
2.3.2.3 Harlequin ichthyosis
The most severe form of ichthyosis is harlequin ichthyosis (OMIM 242500), which is characterized by
a severe erythrodermic ichthyosis with a distinctive and grotesque appearance at birth. It was invariably
associated with stillbirth or early neonatal death until first surviving case was reported in 1985 (Lawlor
1988; Lawlor and Peiris 1985). Since then, several other survivors have been reported, and the outcome
of these patients has been a severe erythrodermic ichthyosis (Haftek et al. 1996; Prasad et al. 1994;
Roberts 1989). The inheritance pattern of harlequin ichthyosis is assumed to be autosomal recessive.
However, although the molecular mechanism of the disease is unknown, a spontaneously mutated
harlequin ichthyosis mouse line has been reported (Sundberg et al. 1997). The disease locus of these
mice have been mapped to mouse chromosome 19. The corresponding homologous regions in the
human genome are scattered over chromosomes 9, 10, and 11. The responsible gene has never been
cloned neither in the mouse nor in the human, but calpain I, lying on chromosome 19 in mice and on
chromosome 11q13 in human beings, is an interesting candidate gene for harlequin ichthyosis. Calpain
I is a calcium-activated protease and is widely expressed in the epidermis. Recently, poor expression of
calpain I was found in harlequin ichthyosis patients.
2.3.2.4 Bullous ichthyosiform erythroderma (epidermolytic hyperkeratosis)
Bullous ichthyosiform erythroderma (BIE) (OMIM number 113800) is an autosomal dominant disorder
of keratinization which, in its early stages, is associated with blistering. Characteristic histological
findings with lysis and tonofilament clumping in suprabasal keratinocytes suggest an underlying
genetic defect in keratin synthesis involving keratins 1 and 10 (K1, K10) (Ishida-Yamamoto et al.
1992). Subsequently, several groups have described mutations in the highly conserved regions of K1
and K10 (Cheng et al. 1992; Chipev et al. 1992; McLean et al. 1994). Mutations in these regions affect
intermediate filament assembly and integrity and are predicted to disrupt higher filament assembly in a
dominant negative fashion, leading to the collapse of the network and to filament clumping around the
nucleus.
2.3.2.5 Ichthyosis bullosa of Siemens
The clinical picture of ichthyosis bullosa of Siemens (IBS) (OMIM 146800) resembles that in BIE;
however, it appears to be milder (Traupe et al. 1986). IBS and BIE are often clinically distinguishable
from each other because of the similar clinical appearance and variability. However, they can be
discriminated at the molecular level since the type II keratin 2e, which is expressed in the upper
keratinocytes, has been recognized as the defective gene in ichthyosis bullosa of Siemens (Rothnagel et
al. 1994).
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Table 2 Inherited forms of ichthyoses
Classification of ichthyoses Inheritance
Model
Locus Gene/protein
involved
Reference
Major primary ichthyoses
Ichthyosis vulgaris AD - -
X-linked recessive ichthyosis X-linked
recessive
Xp22.3 STS/Steroid sulphatase (Yen et al. 1987)
ARCI-Non-bullous ichthyosiform
erythroderma (CIE)
AR (AD) 14q11? TGM 1/
Transglutaminase 1?
(Laiho et al. 1997; Hennies et
al. 1998; Pigg et al. 1998)
ARCI-Lamellar ichthyosis (LI) AR (AD) 14q11,
2q33-35,
3p21
19p13.1.-
13.2
TGM 1/
Transglutaminase 1
(Huber et al. 1995; Russell et
al. 1995; Parmentier et al.
1996; Fischer et al. 2000;
Virolainen et al. 2000)
Harlequin ichthyosis AR - -
Bullous ichthyosiform
erythroderma (BIE)
(epidermolytic hyperkeratosis)
AD 12q KRT1/10 /Keratin 1/10 (Cheng et al. 1992; Chipev et
al. 1992)
Ichthyosis bullosa of Siemens
(IBS)
AD 12q KRT2e /Keratin 2e (Rothnagel et al. 1994)
Ichthyosis hystrix AD - -
Ichthyosiform syndromes
Netherton’s syndrome
(ichthyosis linearis circumflexa)
AR 5q32 SPINK5 /Lympho-
epithelial Kazal-type
related inhibitor
(Chavanas et al. 2000)
Sjögren-Larsson syndrome AR 17p11.2 FALDH/fatty aldehyde
dehydrogenase
(De Laurenzi et al. 1996)
Neutral lipid storage disease
(Chanarin-Dorfman syndrome)
AR - -
Refsum’s disease AR 10p PAHX / phytanoyl
CoA dehydrogenase
(Jansen et al. 1997; Mihalik et
al. 1997)
Kallman’s syndrome X-linked
recessive
Large
deletion
of Xp
Several genes in Xp (Ballabio et al. 1988)
Multiple sulphatase deficiency
syndrome
AR - -
X-linked dominant ichthyosis
(X-linked dominant
chondrodysplasia punctata,
Happle’s sdr, )
X-linked
dominant
- -
Ichthyosis Brittle hair Impaired
intelligence Decreased fertility and
Short stature syndrome
(trichothiodystrophy) (IBIDS)
AR 19q13.2-
13.3
ERCC2 and 3/
Excision repair,
complementing
defective in chinese
hamster
(Takayama et al. 1996; Weeda
et al. 1997)
Keratitis Ichthyosis and Deafness
syndrome (KID)
AD? - -
Congenital Hemidysplasia with
Ichthyosiform erythroderma or
naevus and unilateral Limb Defects
(CHILD)
X-linked
dominant
- -
Ichthyosis follicularis with alopecia
and photophobia
X-linked
recessive?
- -
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2.3.3 Major ichthyosiform syndromes
2.3.3.1 Netherton’s syndrome
Nethertons’s syndrome (OMIM number 256500) is the commonest of the ichthyotic syndromes, with
an incidence of 1:100 000 (Netherton 1958). It is an autosomal recessive condition characterized by
congenital ichthyosis (hyperkeratosis is mild), a special hair defect (trichorrexis invaginata or “bamboo
hair”) and atopic manifestations (atopic dermatitis, hayfever, high serum IgE levels, and
hypereosinophilia) (Griffiths et al. 1998). Recently, the disease gene SPINK 5 (serine protease
inhibitor, Kazal type 5), encoding the serine protease inhibitor LEKTI (lympho-epithelial Kazal-type
related inhibitor), was found from 13 families with Netherton’s syndrome (Chavanas et al. 2000). The
mechanism by which LEKTI can cause the features of the disease is still unclear. However, as the
LEKTI is expressed in thymus, it may cause abnormal maturation of T-lymphocytes, which may disturb
normal responsiveness to allergens and lead to atopic manifestations. LEKTI may also regulate yet
unknown signaling pathways.
2.3.3.2 Sjögren-Larsson syndrome
Sjögren-Larsson syndrome (OMIM 270200) is an autosomal recessive neurocutanaous condition
comprised of congenital ichthyosis, spastic diplegia, retinopathy, and mild to moderate mental
retardation (Jagell et al. 1981; Sjögren and Larsson 1957). A defect in essential fatty acid metabolism
has been detected, specifically in the enzyme fatty aldehyde dehydrogenase (De Laurenzi et al. 1996).
Affected patients have impaired fatty alcohol oxidation and consequently accumulate long-chain
alcohol in their tissues, which is assumed to be responsible for symptoms of the disease.
2.3.3.3 Refsum disease
Refsum disease (OMIM 266500) resembles in part Sjögren-Larsson disease: it is a neurocutaneous
disorder, and the causative agent is involved in fatty acid metabolism (Refsum 1946). However, the
disease is usually diagnosed only in early adult life, since clinical features like retinitis pigmentosa,
cerebellar ataxia, peripheral polyneuropathy, ichthyosis, and increased cerebrospinal fluid protein
progress slowly. This defective gene in Refsum disease is phytanoyl-CoA hydroxylase, which is a
peroxisomal protein catalyzing the first step in the oxidation of phytanic acid (Jansen et al. 1997;
Mihalik et al. 1997). This gene defect leads to accumulation of phytanic acid to tissues. Phytanic acid is
derived from the diet and cannot be synthesized by human tissues. Effective dietary therapy is available
if the diagnosis is made in time (Djupesland et al. 1983; Gibberd et al. 1979).
2.3.3.4 Ichthyosis Brittle hair Impaired intelligence Decreased fertility and Short stature syndrome
(IBIDS)
IBIDS (OMIM number 601675) is a rare and heterogeneous genodermatosis first described in 1968
(Pollit et al. 1968). Major features are described in its name. The central feature of the disorder is a
reduced amount of sulphur-containing amino acids, cysteine and proline, in the hair. Clinical
photosensitivity is present in approximately 50% of IBIDS patients but is not associated with an
elevated frequency of cancers. Virtually all photosensitive IBIDS patients have a deficiency in the
nucleotide excision repair (NER) of UV-induced DNA damage that is indistinguishable from that of
xeroderma pigmentosum (XP) complementation group D patients. Two genes encoding DNA repair
genes ERCC2 and 3 (Excision repair complementing defective in Chinese hamster) had been suggested
as disease causing gene in IBIDS. ERCC2 gene defect has been found altogether in 12 patients(Botta et
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al. 1998; Coin et al. 1998; Takayama et al. 1997) and ERCC3 defect in two mildly affected patients
(Weeda et al. 1997). ERCC2 and 3 has DNA helicase activity and they are subunits of the
transcription/repair factor TFIIH (Transcription factor II H) (Schaeffer et al. 1993). TFIIH is a basal
transcription factor with a second function in DNA repair. Thus, mutations in TFIIH components may,
in addition of a repair defect, also cause transcriptional insufficiency, which may explain part of the
other clinical features of IBIDS.
2.3.4 Acquired ichthyoses
Acquired ichthyoses are generally associated with an underlying pathology such as a malignancy.
Clinically, the ichthyosis of the patients is mild, resembling ichthyosis vulgaris. The most commonly
reported malignancy associated with acquired ichthyosis is Hodgkin’s disease (Cooper et al. 1980;
Sneddon 1955). The production of transforming growth factor α, a potent enhancer of keratinocyte
migration and proliferation, has been proposed as a causative factor (Lucker and Steijlen 1995).
Acquired ichthyosis can also be detected with other malignancies, such as multiple myeloma, breast,
lung, and cervix cancers (Bluefarb 1955; Flint et al. 1975). Acquired ichthyosis may occur with chronic
metabolic derangement such as malnutrition or malabsorbtion which may disturb lipid or possibly
vitamin absorption (Flint et al. 1975). Some endocrinological diseases, such as hypopituitarism, or
granulomatous diseases, such as sarcoidosis, are also associated with ichthyosis (Dykes and Marks
1977; Feind-Koopmans et al. 1996). Several drugs which affect cholesterol or lipid metabolism in the
skin, such as nicotinic acid or hydroxy-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors,
can also sometimes predispose to ichthyosis (Williams et al. 1987).
2.4 AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS (ARCI)
2.4.1 Classification and clinical features
2.4.1.1 Lamellar Ichthyosis (LI) and Congenital Ichthyosiform Erythroderma (CIE)
In the Anglo-Saxon literature, two major types of autosomal recessive ichthyosis are distinguished:
congenital ichthyosiform erythroderma (CIE) (OMIM 242100) and lamellar ichthyosis (LI) (OMIM
242300) (Williams and Elias 1985). Terminology used in the description of ARCI is confusing; some
authors use the term LI for both LI and CIE patients, but most authors consider them separate entities.
There is little data about the epidemiology, but estimated incidences are 1:300 000 for CIE and 1:500
000 for LI (Griffiths et al. 1998; Wells and Kerr 1966). The mode of inheritance is usually autosomal
recessive, but dominant cases have been described in both disease groups (Traupe et al. 1984). Both LI
and CIE patients are often born as collodion babies, encased in a plastic-like collodion membrane,
which peels away within a few weeks. Collodion babies are in risk of sepsis and dehydration, but
usually survive. Later in life, scaling in CIE patients is usually generalized and whitish, and
erythrodermia is present. In contrast, in LI, the scales are thicker and brownish, and erythrodermia is
variable. Some patients have an intermediate phenotype between LI and CIE, and a clear-cut diagnosis
may be difficult to make. In both patients groups, the severity of the phenotype varies. The rare subtype
of LI phenotype is an appearance of ichthyosis only on the trunk of the patients. In this type of LI, “ the
bathsuit type,” the extremities of the affected individual have relatively normal skin, whereas the trunk
is strongly affected.
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2.4.1.2 Ultrastructural classification
An electron microscopic classification was presented by Anton-Lamprecht and other investigators
between 1980 and 1994 (Anton-Lamprecht 1992; Arnold and Anton-Lamprecht 1988; Niemi et al.
1991; Niemi et al. 1994; Niemi et al. 1992; Niemi et al. 1993). In this classification, ARCI patients are
divided into four different groups according to electron-microscopic findings. This classification is in
use in some European countries such as Finland, Sweden, and Germany.
IC type I: Clinically, type I patients correspond to CIE patients. They have generalized fine scaling with
variable erythroderma, but there is marked heterogeneity among affected individuals. Ultrastructurally,
clear-cut criteria are lacking, although the presence of lipid droplets in cornified cells is detectable.
However, lipid droplets are not a specific finding for ichthyoses (Niemi et al. 1994) (See Figure 1A in
publication II).
IC type II: Of the IC groups, type II is the most clearly defined. Ultrastructurally, crystalloid structures
called cholesterol clefts appear in the thickened corneal layer as a rather specific ultrastructural marker
for IC type II. Patients have a clinical picture consistent with classic lamellar ichthyosis with its large
brown scales (Niemi et al. 1991) (See Figure 1B in publication II).
IC type III: In this group, elongated perinuclear membrane structures, abnormal keratinosomes, and
vesicular complexes in the upper epidermal and cornified cells are detectable by electron microscopy.
The clinical picture differs from the other types in that the onset of ichthyosis is variable. Ichthyosis as
well as erythroderma can be patchy or generalized, and in these patients flexures are typically ichthyotic
(Niemi et al. 1992) (See Figure 1C in publication II).
IC type IV: Only a few cases of type IV ichthyosis have been described. The clinical course in
newborns may be severe, and infants are at risk of respiratory distress syndrome. Later, the clinical
picture is milder, and follicular hyperkeratosis gives the skin a goose skin-like appearance. In electron
microscopy, the packages of trilaminar membrane structures in upper epidermal and cornified cells are
a typical finding (Niemi et al. 1993) (See Figure 1 D in publication II).
2.4.2 Molecular genetics of ARCI
The first hints as to pathogenesis of ARCI were revealed in 1993 when a diminished
immunohistochemical staining of TGase 1 was found in three LI patients (Hohl et al. 1993). A genetic
study of inbred and outbred families demonstrated linkage to a region on chromosome 14q11, where
the TGM 1 gene is located (Russell et al. 1994). Mutations in the TGM 1 gene resulting in reduced
TGase 1 activity were identified soon after (Huber et al. 1995; Russell et al. 1995). To date over 30
different mutations have been identified in the TGM 1 gene by several research groups (Study I and II)
(Bichakjian et al. 1998; Candi et al. 1998; Hennies et al. 1998; Hennies et al. 1998; Huber et al. 1997;
Parmentier et al. 1995; Petit et al. 1997; Pigg et al. 1998; Tok et al. 1999). Most of these are point
mutations or small deletions resulting in amino acid substitutions, stop codons, or splicing defects.
However, not all ARCI patients carry the TGM 1 gene defect (Bale et al. 1996; Huber et al. 1995). Like
many other genetic diseases, ARCI is genetically heterogeneous, and in addition to the TGM 1 locus a
second locus for ARCI has been identified on chromosome 2q33-35 (Parmentier et al. 1996). However,
the defective gene in that region remains still unknown (Parmentier et al. 1999). The most recent
linkage studies have revealed three new chromosomal loci for ARCI in chromosomes 3p21, 19p13.1.-
13.2, and 19p12-q12, bringing the total number of ARCI loci to at least five (Fischer et al. 2000) (Study
III). Unexpectedly, none of the other TGM genes are co-localized to the linkage intervals. Because a
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great number of affected individuals show no linkage with any of these loci, there most probably are
several other loci linked to ARCI.
2.4.3 Therapeutic strategies of ARCI
Treatment of ARCI involves the use of various topical emollients such as urea, propylene glycol, and
alpha-hydroxy acids (AHA), and a combination of lactic acid and propylene glycol, as well as retinoids
(oral vitamin A derivatives) (Gånemo and Vahlquist 1997; Steijlen et al. 1994). The mechanism of the
effectiveness of retinoid therapy in ARCI is unclear. However, therapeutic results are often incomplete,
and side-effects are common. Recently, some interesting gene-therapeutic experiments have been made
to restore the TGase 1 activity (Choate et al. 1996) (Choate et al. 1996) (Choate and Khavari 1997).
These studies used the human skin/immunodeficient mouse xenograft model. TGase 1-deficient
primary keratinocytes from LI patients were transfected with functional TGase 1. These keratinocytes
were then grafted onto immune deficient mice. Engineered LI epidermis on the immunodeficient mouse
expressed TGase 1 normally, whereas TGase 1 expression was absent from unengineered LI murine
epidermis. Successful phenotypic correction in engineered LI epidermis was achieved, but transgene
expression loss and loss of corrected phenotype appeared from week 6 after grafting (Choate et al.
1996). Despite the limited results, gene replacement strategies in ARCI hold the promise of novel
therapeutic approaches.
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2.5 SEARCH FOR DISEASE GENES FOR MONOGENIC DISORDERS
2.5.1 Methods for identifying genes for human monogenic disorders
A number of approaches are possible for cloning disease genes of inherited disorders (Collins 1995).
The main approaches include:
1. Functional cloning. Traditionally, cloning was performed by the functional cloning approach in
which the identification of a defective gene was based on information about the basic biochemical
defect without a reference to chromosomal map position. However, in most genetic diseases the
biochemical defect is unknown, a limitation which restricts the usefulness of this strategy
2. The candidate gene approach. In most genetic diseases, some knowledge of pathogenesis exists
which makes possible to make ”an educated guess” as to the possible defective genes. For example,
in the genodermatoses some chromosomal regions include gene clusters of epidermal
differentiation genes or keratins both of which have been shown to be defective in some
genodermatoses (Cheng et al. 1992; Maestrini et al. 1996; Mischke et al. 1996; Rosenberg et al.
1988). Currently, an increasing amount of information from animal models provides ideas about
possible candidate genes through the use of comparative genomic strategies.
3. Positional cloning. In positional cloning, the search for the defective gene is based solely on its
chromosomal localization. The power of positional cloning is that it can recognize disease genes
without any knowledge of the disease mechanism. This can result in determination of a disease
gene which ”nobody would ever have guessed.” The positional candidate approach refers to the
identification of potential candidate genes from a restricted chromosomal region. A typical scheme
for positional cloning is shown in Figure 7.
2.5.2 Genetic mapping
In the positional cloning strategy for a human disease gene, the second step after collecting suitable
families is to identify the disease locus by use of polymorphic markers and analysis of their segregation
in pedigrees. In a simple monogenic disorder like ichthyosis, there should be only one disease locus in
all affected individuals within a single pedigree. To localize disease loci, genetic maps of the human
genome are used.
2.5.2.1 Genetic maps and markers
Polymorphisms, simply defined as sequences that vary between individuals, exist in the human
genome. Different types of polymorphisms have been utilized in the creation of genetic maps. The first
human genetic map, containing approximately 400 loci, was based on restriction fragment length
polymorphisms (RFLPs) (Donis-Keller et al. 1987). The drawback of this restriction-enzyme based
mapping method is the labor intensiveness and low information content of biallelic markers. RFLPs
were succeeded by minisatellite markers-variable number of tandem repeats (VNTRs)-which have a
higher information content (Jeffreys et al. 1985; Nakamura et al. 1987). The discovery of
microsatellites (STRs or short tandem repeats) and PCR techniques finally led to the modern technique
of detecting microsatellites by PCR and polyacrylamide gel electrophoresis (PAGE) (Miesfeld et al.
1981; Weber and May 1989). This progress started the spate of so-called second-generation maps of the
human genome.
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Figure 7. Principle of positional cloning approach. The first steps include a collection of suitable families
and linkage studies of the genome (low resolution mapping). After identification of a disease locus, there
follows high resolution mapping; restriction of the critical region (e.g. by linkage disequilibrium methods). If
the sequence and transcripts of the region are mostly unknown, a physical mapping phase results. In this
phase, a contig, an arranged collection of sequences of the region of interest, is made. A visible cytogenetic
rearrangement, if available, can greatly assist both the low and the high resolution mapping phases. When
the smallest possible region is achieved, all the transcripts in the area are identified, usually by utilizing
ESTs (partial cDNA sequences) mapped to the region. Finally, the disease-causing mutation is identified in a
candidate gene or in the novel transcript by comparing sequences of affected individuals and healthy
controls. At present a growing amount of transcript data has changed the positional cloning approach
towards a positional candidate approach, which combines knowledge of map position with the increasingly
dense human transcript map. Currently, when a human sequencing project is near its end, the laborious
physical mapping phase is less often needed, whereas the use of different databases and computational
prediction programs in the interpreting of sequence data, “in silico” cloning, becomes increasingly important
(Courtesy from Dr. Höglund).
Fluorescence-based, semi-automated typing of microsatellite markers is currently the method of choice
for genome-wide mapping projects, although SNP mapping is emerging. Advantages of microsatellite
markers are their high informativeness and relatively dense distribution (once in every 30 kb)
throughout the genome (Weber 1990). In genetic maps, the genetic distance is usually expressed in
centimorgans (cM). One centimorgan corresponds to the average distance in which 1 recombination in
every 100 meiosis occurs. The human genetic map spans 3690 cM on average, but the male (2644 cM)
and female (4481 cM) map differ considerably, indicating that recombination events are much more
common in females (Gyapay et al. 1994). Today, several genetic microsatellite-based maps exist,
comprised of thousands of markers. The most common type of microsatellites is dinucleotide repeats.
Microsatellites still have disadvantages, such as manual gel loading, which makes complete
automatization difficult, and PCR amplification is costly and time-consuming. Complete
automatization would facilitate the laborious mapping projects of complex diseases, for which
hundreds of affected individuals are genotyped. Therefore, attention has recently turned to single-
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nucleotide polymorphisms (SNPs), since they are the most suitable for automated genotyping, for
example by DNA microarrays, and a proportion of SNPs are thought to contribute to disease
susceptibility (Brookes 1999; Collins et al. 1999). SNPs are the most frequently occurring
polymorphisms in humans, with an estimated frequency of 1/1000 bp. SNPs are distributed uniformly
on both the coding and non-coding regions of the genome. Large-scale SNP discovery efforts will
provide a dense, third-generation map of the human genome. Several organizations, such as the US
NIH and the Genset company, have begun their own programs to detect tens of thousands SNPs, and a
joint academic/drug industry venture called the SNP consortium is committed to finding 300 000 SNPs
and mapping half of them within a few years. Collectively, it is reasonable to expect many hundred
thousand SNPs to enter the public databases in the near future (Brookes 1999).
Creating modern genetic and physical maps of the human genome has been a result of international
cooperation within the Human Genome Project (HGP). It was originally initiated in the United States in
the late 1980s, but was soon extended to several other countries, and an International Human Genome
organization was founded to coordinate the projects (Collins and Galas 1993). The results of the HGP
are convincing. For example, a genetic map of under 2.0 cM density, and sequence-tagged site (STS)-
anchored physical maps of 200-500 kb density have been created (Murray et al. 1994) (Dib et al. 1996;
Hudson et al. 1995). The EST database contains 2 204 609 human ESTs (situation on 21th July 2000,
dbEST release 072100, http://www.ncbi.nlm.nih.gov/dbEST/dbEST_summary. html), and many of them
have been positioned on the physical map. The main focus of the HGP is now on completing the
sequencing of the human genome (Collins et al. 1998). Two alternative approaches to determine the
human genome sequence have been proposed. The clone-by-clone approach constructs an organized
clone map which covers the human genome and which is then sequenced. In contrast, the shotgun
sequencing strategy sequences unmapped clones, which are assembled afterwards ( The Sanger Centre
1998) (Weber and Myers 1997). The public domain HGP follows a clone-by-clone approach and has
published the sequences of two human chromosomes, chromosomes 22 and 21, and announced on 26th
June in a press release that the draft human sequence (sequencing finished, assembly not) is competed
(Hattori et al. 2000). A private company, Celera Genomics, which utilizes the whole genome shotgun
sequencing strategy, has already declared to have completed the draft sequence and the first assembly of
the sequence. The high quality sequence (sequence and assembly are finished) is promised for 2003 in
the public HGP; the amount of high quality sequence in July 2000 was 21%: specifically 665 654 000
base pairs are now sequenced and organized precisely within the human genome. The HGP also targets
sequencing of other organisms. A number of genomes of microbial organisms such as Saccaromyces
cerevisiae have been sequenced, as well as two multicellular organisms, Caenorhabditis elegans and
Drosophila melanogaster (Adams et al. 2000; The C. Elegans Sequencing Consortium 1998; Mewes et
al. 1997).
2.5.2.2 Statistical analysis in monogenic disorders –linkage analysis
The most common approach to genetic mapping is linkage analysis, which has been successfully
applied to hundreds of simple monogenic diseases. Two loci lying close together on the same
chromosome are said to be “linked” if they have a tendency to co-segregate. Alleles at loci on the same
chromosome should co-segregate at a rate related to the distance between them in the chromosome. The
specific statistical figure, the recombination fraction (θ), describes this probability of a recombination
event as occuring between the two loci. The recombination fraction ranges from θ = 0 for loci which
are tightly linked to θ = 0.5 for loci which are far apart (approaching random segregation). The
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recombination fraction can be taken as a measure of the genetic distance between loci so that a map
distance of 1cM corresponds approximately to a recombination fraction of 0.01 (Terwilliger and Ott
1994).
In linkage analysis, the segregation of alleles at a disease locus and at a polymorphic marker locus is
followed in the pedigree to determine whether the two loci tend to co-segregate more often than if they
segregated independently (for example, if they were not physically close together in the same
chromosome). The object of the linkage analysis is to estimate the recombination fraction between the
disease and the marker loci, and, in case a recombination fraction is under 0.5, to determine whether the
finding is significant. The most commonly used statistical value to express the likelihood of linkage is
the LOD score (Morton 1955). LOD score is the logarithm to the base 10 of the likelihood ratio (the
chance of observing the linkage of the trait and marker loci at a given recombination fraction to the
chance given no linkage). A LOD score is considered as significant at a given recombination fraction if
it is greater than 3. A LOD score under –2 indicates significant evidence for exclusion of linkage.
Computer methods have been developed to facilitate linkage calculations for several families and
marker loci (Ott 1974) (Lathrop and Lalouel 1984; Lathrop et al. 1984; Lathrop et al. 1986).
2.5.2.3 The genetic isolate of Finland and an internal isolate of Larsmo archipelago
Finland has been a representative example of the power of a genetic isolate in cloning of inherited
disease genes. Analysis of mtDNA and Y chromosomal data in the Finns has revealed an exceptionally
low genetic diversity of Finns compared to that of other European populations (Sajantila et al. 1996);
Kittles, 1998 #763]. This reflects the peculiar population history of Finland. Although Finland is likely
to have been inhabited without interruption since the glacial period, the majority of the genes of today`s
Finnish population are thought to originate from recent small founder populations some 2000 years ago
(Nevanlinna 1972). With time, the population has slowly grown, and although it experienced several
bottlenecks, during the last century the population has rapidly increased to its present 5.1 million.
Religious and linguistic barriers, their geopolitical position, and most importantly geography have
ensured that the Finns have remained in local and national isolation. This situation has resulted in the
high prevalence of certain inherited diseases, grouped under the label "Finnish disease heritage,"
including about 30 mostly recessive genetic traits which are exceptionally common in Finland, but are
rare among other populations (de la Chapelle 1993; Norio et al. 1973; Peltonen et al. 1999).
Mapping of monogenic disease genes an isolated population like Finland offers advantages over
mapping of heterogeneous populations. These include:
1. The high incidence of some recessive disorders, which determines the sufficient number of families
for linkage studies.
2. The high incidence of remotely consanguineous marriages, which enables utilization of efficient
mapping methods, such as homozygosity mapping.
3. Monogenic disorders are likely to be caused by one or few founder mutations, making linkage
disequilibrium methods feasible.
Specific epidemiological data are lacking: no evidence exist that ARCI is enriched in Finland and is a
part of the Finnish disease heritage. Despite this, internal isolates such as the archipelago of Larsmo
(Luoto) in Osthrobotnia are highly consanguineous and provide families suitable for a random search of
new disease loci (Figure 8). A good example of this is a collection of families and mapping of a disease
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locus for tibial muscular dystrophy, “Larsmo disease”(Haravuori et al. 1998; Udd 1992) .
Figure 8. Location of the Larsmo
Archipelago in the coast of Ostrobotnia near
the town of Pietarsaari
Larsmo was probably not inhabited until the 13th century, and the origin of the founders is unknown.
Because migration between the island and the mainland was very limited until this century,
consanguineous marriages have thus been common as far back as family histories can be traced to the
17th century (Udd 1992).
2.5.2.4 Homozygosity mapping
Rare recessive diseases in the offspring of consanguineous parents usually arise because the affected
individuals have inherited two identical defective copies of the same gene from a common ancestor.
Homozygosity mapping is a strategy to find the chromosomal localization of a recessive disease gene
by identifying genomic regions of homozygosity in patients born from consanguineous marriages
(Lander 1987). By definition, affected offspring of consanguineous marriages should also be
homozygous for genetic markers near the responsible disease locus. The homozygosity mapping
approach was first applied in the localization of the genes causing ataxia with selective vitamin E
deficiency and alkaptonuria (Ben Hamida et al. 1993; Pollak et al. 1993). Isolated populations provide
an opportunity to apply this strategy even if only a few affected individuals are available for the primary
genome search. A good example is the mapping of the infantile-onset spinocerebellar ataxia (IOSCA)
locus on chromosome 10q23.3-24.1 by use of only four affected individuals (Nikali et al. 1995).
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3 AIMS OF THE PRESENT STUDY
Prior to this study, the TGM 1 gene was found to be the disease-causing gene in ARCI. Nothing was
known about the molecular background of Finnish ARCI patients. Thus the main goal of the project
was to characterize the molecular genetics of ARCI in Finland. The specific aims of this study were:
1. To detect and characterize the TGM 1 mutations in ARCI in Finnish patients
2. To compare the clinical phenotype and histopathological findings of the patients with their
genotype
3. To search for a new gene locus underlying the ARCI phenotype by genome-wide screening
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4 MATERIALS AND METHODS
4.1 CHARACTERIZATION OF TGM 1 MUTATIONS
4.1.1 ARCI patients
We studied 49 patients from 38 Finnish families were studied. Patients were collected among ARCI
patients diagnosed with ichthyosis congenita types I-IV by electron microscopy at the Department of
Dermatology of Helsinki University Central Hospital prior to this study. There were 24 type I, 10 type
II, 6 type III and 2 type IV ARCI patients, and 8 patients did not belong to any of these groups; 117
unaffected family members also took part in the study. The diagnosis was based both on clinical
findings and on electron microscopy. None of the individuals studied had neurological symptoms
suggesting syndromic ichthyosis. The study was approved by the Ethics Committee of the Department
of Dermatology of the Helsinki University Central Hospital.
4.1.2 Isolation of DNA and DNA-amplification
Genomic DNA was extracted from leukocytes by standard procedures (Sambrook et al. 1987). To
search for mutations, 15 exons and exon intron boundaries of the TGM 1 gene were amplified by PCR
(Saiki et al. 1988). The reaction conditions were optimized for each individual region. Radioactive
PCR for single-strand conformation polymorphism (SSCP) was performed by adding 2.5 µCi of α-32
³²P dCTP or dGTP (Amersham, Aylesbury, UK) to each PCR assay.
4.1.3 Mutation screening and characterization
SSCP analysis
The radioactive PCR products were analyzed by SSCP (Orita et al. 1989) (Study I). The PCR products
were diluted 1:5 with 0.1% sodium dodecyl sulfate (SDS) and 10 mM EDTA and mixed with an equal
volume of stop solution (Sequenase kit; US Biochemicals, Cleveland, OH, USA). The samples were
denatured at 96°C for 5 min, cooled briefly on ice, and loaded on an 8 % polyacrylamide gel (60:1
acrylamide/bisacrylamide; BioRad, Richmond, CA, USA) with 5% glycerol. Bands were visualized by
autoradiography.
4.1.3.1 Sequence analysis
A solid-phase sequencing strategy was used for the regions where mobility shifts were detected in
SSCP (Study I). PCR was performed using primer pairs in which one was biotinylated at its 5´ end. The
PCR product was purified with streptavidin-coated microbeads (Fluoricon; Baxter, Mundelein, IL,
USA) (Syvänen et al. 1989). A total of 25 µl of the PCR product was incubated with microbeads in
TENT buffer (0.01% Tween 20, 1 mM EDTA, 50 mM NaCl, and 40 mM Tris-HCL, pH 8.0 to 8.8) for
0.5 hours at room temperature. The sample was washed with TENT buffer, and the bound PCR product
was denatured by incubation for 5 minutes in 50 mM NaOH. The unbiotinylated strand was removed
by washing the product twice with TENT buffer. The single-strand template was sequenced directly by
the dideoxy chain termination method of Sanger (Sequenase version; US Biochemicals) (Sanger et al.
1977).
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4.1.3.2 Solid-phase minisequencing
After detection of the nucleotide alterations, the samples from all patients, family members, and healthy
controls were screened for each mutation by solid-phase minisequencing, which unequivocally
identifies the genotype (Syvänen et al. 1990) (Study I). PCR for the minisequencing reaction was
performed asymmetrically with one biotinylated primer and one unbiotinylated primer. The PCR
product and phosphate-buffered saline/0.1% Tween in bovine serum albumin were added to
streptavidin-coated microtiter wells (Streptavidin-coated combiplate; Labsystems, Helsinki, Finland).
The samples were incubated and washed afterwards five times with TENT buffer. The unbiotinylated
strand was removed by denaturing, and a reaction mixture containing a detection primer, 3H dNTP
(Amersham) Taq DNA polymerase (Promega, Madison, WI, USA), was added to each well, and the
samples were incubated and washed as above. The hybridized primer was released by denaturing, and
the radioactivity resulting from the incorporated 3H -labeled nucleotides was measured from each well
in a liquid scintillation counter (Microbeta; Wallac, Turku, Finland). The genotype was defined by the
ratios of incorporated mutant versus normal nucleotides (r value). To evaluate the frequency of the
identified point mutations in the general population, DNA samples of about 400 blood donors were
screened. The screening method was identical to that described above.
4.1.3.3 Haplotype analysis
Haplotypes of the affected individuals with TGM 1 mutations were detected as described in study I.
Five polymorphic markers flanking TGM 1 gene were amplified by PCR, separated by electrophoresis
and detected either by 5´end-labeled with ³²P-γATP (Amersham. Little Chalfont, UK) or by silver
staining of the gels.
4.1.3.4 Modeling
The structural consequences of the four missense mutations were predicted by utilizing the three-
dimensional structure of the FXIII A-subunit zymogen dimer, determined by single-crystal X-ray
diffraction (Yee et al. 1994), as a template for creating a homology model of human Tgase 1 (study I).
Coordinates for the factor XIII structure were obtained by use of the program X-PLOR (Brunger 1992).
Models of the TGase 1 mutant structures were generated with the computer program O (Jones et al.
1991), and figures were drawn with the program MOLSCRIPT (Kraulis 1991).
4.1.3.5 Creating the expression construct, mutagenesis, and transfection
To explore the consequences of the Arg-142-Cys mutation, we performed in vitro expression studies in
COS cells utilizing the homology of the FXIII A subunit to TGM 1 (Study I). FXIII A-subunit cDNA
was inserted into a SV40poly expression vector, and the specific Arg-78-Cys mutation in factor XIII
corresponding to the mutation site Arg-142-Cys in the TGM1 gene was created by oligonucleotide
(Stacey and Schnieke 1990). COS cells were transfected with the mutant SV40poly cDNA construct by
the DEAE-dextran-chloroquine method (Sussman and Milman 1984). Cells were harvested after 48 to
94 hours, and the consequences of the mutations were analyzed.
4.1.3.6 Analysis of transfection efficiency and steady state mRNA levels
The transfection efficiency and the steady state mRNA levels of the mutant FXIII in transfected cells
were studied by double transfecting the cells with an equal amount of wild type and mutant clones
(Study I). The cells were harvested after 48 hours and the nuclear and cytoplasmic fractions were
separated by lysis buffer and centrifugation (Jalanko et al. 1995). The ratio of the two clones in DNA
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(nuclear fraction) and RNA (cytoplasmic fraction) were analyzed after PCR by solid-phase
minisequencing.
4.1.3.7 Western blot
The amount of mutant FXIII polypeptides accumulating inside the cells was studied by immunoblotting
of the individually transfected cell homogenates (Study I). The cells were harvested 72 hours after
transfection and analyzed by 10% SDS-polyacrylamide gel electrophoresis and polyclonal,
monospecific anti- FXIII A-subunit antibody (Clotimmun, Behringwerke AG, Marburg, Germany)
(Laemmli 1970). Visualization was performed by the enhanced chemiluminescence (Paunio et al.
1994).
4.1.3.8 Metabolic labeling and immunoprecipitation
The intracellular stability of the mutant proteins was studied by pulse-chase analysis (Study I). The
transfected cells were metabolically labeled during a one-hour radioactive pulse with
35
S-methionine
(Amersham) Aylesbury, U.K), whereafter the cells were monitored after variable chase periods (4, 8,
and 24 hours). FXIII polypeptides in the transfected cell lysates and chase media were analyzed by
immunoprecipitation with fixed FXIII A-subunit and Staphylococcus Aureus antibody
(Immunoprecipitin, Gibco BRL, Gaithesburg, MD) (Proia et al. 1984). The precipitated proteins were
analyzed in 10% SDS-PAGE gels and visualized by autoradiography.
4.1.3.9 Transglutaminase activity measurement by ammonia release assay
The enzymatic activity in the transfected cells was studied by the Berichrom activity assay
(Behrichrom, Behringwerke AG, Marburg, Germany ) (Lorand et al. 1972) (Study I).
4.2 SEARCH FOR A NEW GENE UNDERLYING ARCI
4.2.1 Genotyping
4.2.1.1 Family
Only one family was selected for the genome scan due to the expected genetic heterogeneity of the
ichthyoses (Study III). This family originated from a known genetic subisolate in Finland, the
archipelago of Larsmo off the coast of Ostrobothnia. X-linked ichthyosis was excluded by measuring
the steroid sulphatase activity from one patient in the family, and the clinical picture and the pedigree
profile were also not suggestive of X-linked ichthyosis. In histologic examination, the granular layer
was present in all patients, excluding ichthyosis vulgaris. All affected individuals displayed a non-
lamellar, non-erythrodermic phenotype which resembled neither classic LI nor classic CIE (study III).
4.2.1.2 Candidate genes
The candidate gene approach served as the first strategy (Study III). We selected five possible
chromosomal loci, the TGM 2 and 3 locus in 20q11.2, Keratin loci in 17q and 12q11-q13, the second
locus for ARCI in 2q33-q35 and the epidermal differentiation complex in 1q (Parmentier et al. 1996;
Wang et al. 1994; Yoon et al. 1994). DNA was amplified by the touchdown-PCR procedure (Don et al.
1991). PCR products were then pooled so that at most four PCR products of different sizes were pooled
and gel electrophoresis was run on an ALF express automated sequencer (Pharmacia Biotech).
Genotypes were analyzed by AlleleLinks™ 1.0 software package (Pharmacia Biotech).
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4.2.1.3 Genome scan
After excluding the candidate genes, a genome-wide scan was performed using 370 highly polymorphic
microsatellite markers of the Cooperative Human Linkage Center with fluorescent label (Dubovsky et
al. 1995) (Study III). The average intermarker distance was 9.3 cM, the largest gaps being 24 cM on
chromosomes 1 and 20.
4.2.2 Statistical analysis
4.2.2.1 Linkage analysis
Linkage analysis was performed assuming an autosomal recessive mode of inheritance for the ARCI
gene, with an estimated gene frequency of 10-3 in the Finnish population, and equal recombination
rates for males and females (Study III). Because of the early onset of the disease, complete penetrance
could be assumed. Data simulation analysis was performed by the SLINK option of the LINKAGE
package of software (Ott 1989; Weeks et al. 1990).The two-point LOD score was calculated by the
MLINK option of the LINKAGE package (Cottingham Jr et al. 1993; Lathrop and Lalouel 1984) and
multipoint linkage analysis were performed with the Simwalk2 program (Sobel and Lange 1996).
Allele frequencies were ascertained from both the pedigree and from the unaffected individuals from
Larsmo island.
4.2.2.2 Haplotypes
Microsatellite markers at the ichthyosis locus on chromosome 19 were obtained from Genome Data
Base (http://gdbwww.gdb.org) with the order of the markers and distances between them based on the
metric physical map of chromosome 19 created by the Human Genome Center of Lawrence Livermore
National Laboratory (http://www-bio.llnl.gov/brp/gebnome/genome.html) (Ashworth et al. 1995)
(Study III). The most likely haplotypes were determined by the Simwalk2 program (Sobel and Lange
1996).
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5 RESULTS AND DISCUSSION
5.1 IDENTIFICATION OF MUTATIONS IN TGM 1 GENE
In the early 1990s, Finnish ARCI patients were collected to be classified into four different categories
by electron microscopy according to criteria created by Anton-Lamprecht (Anton-Lamprecht et al 1992;
Niemi et al. 1991; Niemi et al. 1994; Niemi et al. 1992; Niemi et al. 1993). In 1995, it was found that a
subclass of ARCI patients carried mutations in the TGM 1 gene (Huber et al. 1995; Russell et al. 1995).
Prior to that, nothing was known about the molecular defects underlying the Finnish patients’s
condition. Since these patients were histologically and clinically well-characterized, we decided to
begin investigating molecular defects of this clinically and genetically heterogeneous disease group.
First, 49 affected individuals from 38 families were screened for TGM 1 mutations by SSCP (Study I).
Those patients with positive findings in SSCP were sequenced. Detected mutations were screened for
in affected individuals, family members, and healthy controls by minisequencing. 17 patients from 13
families carried six different mutations: Arg-141-His, Arg-142-Cys, Gly-217-Ser, 3339A to G, Val-
378-Leu, and Arg-395-Leu (Studies I-II). Four of the mutations, Arg-142-Cys, Gly-217-Ser, Val-378-
Leu, and Arg-395-Leu, were novel (Figure 9). All of the mutations except 3339A to G were missense
mutations resulting in single amino acid substitution; 3339A to G, situated in an exon-intron boundary,
leads to a splicing error and subsequent premature termination codon. Most of the patients were
compound heterozygotes. Screening of 400 healthy controls for these mutations showed that the
nucleotide changes observed were unlikely to represent common polymorphic variants in the general
population.
Thus far, we and others have reported over 30 mutations in the TGM 1 gene (studies I-II), (Bichakjian
et al. 1998; Candi et al. 1998; Hennies et al. 1998; Hennies et al. 1998; Huber et al. 1995; Huber et al.
1997; Parmentier et al. 1995; Petit et al. 1997; Pigg et al. 1998; Russell et al. 1995; Tok et al. 1999).
The six mutations detected in this study reflect the general pattern of mutations observed in the TGM 1
gene. Most of the mutations are point mutations resulting in single amino acid substitutions, stop
codons or splicing errors. A few minor deletions or insertions resulting in a frameshift have been
detected, as well as one mutation in the Sp1 binding site in the promoter region, resulting in a reduction
of TGM 1 transcript levels. Reduced TGM 1 activity is a consequence of most mutations. Although the
mutations are generally spread throughout the coding region, there seems to be a moderate clustering of
mutations in the catalytic core domain. We also identified a mutation-prone region in B-sandwich
coding for amino acid residues 141-144 (Study I). The mutation profile of the TGM 1 gene, except the
mutation-prone region mentioned above, is highly reminiscent of the mutation profile of FXIII in the
bleeding disorder coagulation FXIII deficiency (Mikkola and Palotie 1996).
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Figure 9. Stereoviews showing the domain structure of the factor XIII A subunit and the four
novel mutations detected. The three dimensional structure of the factor XIII is shown as a coil
structure with the N- and C-terminals labeled. Since factor XIII’s N-terminal activation peptide is
not conserved in TGM 1, it has been omitted from the figure for clarity. The three regions with an
amino acid deletion in TGM 1 relative to factor XIII, where the two molecules are expected to
differ in structure, are shown as thick dark lines connecting alpha carbon atoms. From the N-
terminus, the four sequentially folded domains in the molecule are: beta sandwich, catalytic core,
and beta barrels 1 and 2. The active site is marked by a (“*”) and the alpha carbon atoms of the
four TGM 1 mutation sites at positions 142, 217, 378, and 395 detected in this study. are shown as
large numbered spheres (Courtesy from Dr. Vivien Yee, Cleveland Clinic Foundation, Ohio).
5.2 CHARACTERIZATION OF TGM 1 MUTATIONS
5.2.1 Mutation-prone region in TGM 1
Two haplotypes, 3-6-5-1-3 and 5-4-5-4-5, were shown to co-segregate with one single mutation, Arg-
142-Cys (see Figure 1 in study I). Moreover, haplotypes seemed to associate with two geographically
different areas of Finland, one in central Finland (haplotype 3-6-5-1-3) and the other in eastern Finland
(haplotype 5-4-5-4-5) (see Figure 2 in study I). These phenomena suggest two separate ancient Arg-
142-Cys mutations in Finland. Closer analysis of the sequence of the Arg-142-Cys region revealed a
CpG dinucleotide region, which is prone to spontaneous mutation. The hypermutability of CpG
dinucleotides (C to T) represents an important and frequent cause of mutation in humans. In eukaryotic
genomes, 5-methylcytosine (5mC) occurs predominantly in CpG dinucleotides, the majority of which
appear to be methylated. Methylation of cytosine results in a high level of mutation, due to the tendency
of 5mC to undergo spontaneous deamination to form thymine. In this mutation-prone region, 9
mutations in the TGM 1 gene resulting in 6 different amino acid substitutions in a number of different
populations have been described thus far.
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5.2.2 Mutational modeling of Arg-142-Cys and Arg-141-His
Because of the interesting features of the mutation prone region, we decided to study the Arg-142
region in more detail (study I). We used FXIII as a template to create a homology model to study the
possible structural consequences of the Arg-142-Cys mutation, since the three-dimensional structure of
TGase 1 has not been determined, and there is considerable amino acid homology (299 residues, 42%)
between FXIII and TGase 1.
From structure-guided alignment of 19 sequences of proteins within the TGase family, Arg 141 and
Arg 142 are absolutely conserved residues. Residues which surround Arg 141 and Arg 142 are
conserved in TGase 1 and F XIII, and thus it is very likely that the local protein structure is conserved
in these regions as well, suggesting the structural importance of these residues.
Both Arg 141 and Arg 142 are found at the interface with the catalytic core domain far from the active-
site catalytic triad residues (>25 Ångströms). The two arginine side-chains are involved in extensive
hydrogen-bonding interactions which serve to stabilize the conformation of β-sandwich loops and,
more importantly, to attach the β-sandwich to the catalytic core domain. Replacement of either of these
arginine residues with other amino acids which disrupt the hydrogen-bonding interactions is predicted
to disrupt or destabilize the interdomain interface. Specifically, the Arg 142 side-chain forms a salt
bridge with the conserved catalytic core Asp 253 residue, and with several main chain carbonyl groups
(Pro 212, Ala 214, and Gly 315) (Figure 10). The introduction of the much smaller cysteine side-chain
in the Arg-142-Cys mutant will abolish all five of these hydrogen bonds. Possible results are (1) an
altered quaternary structure which has a modified substrate binding and recognition surface or is more
susceptible to proteolytic cleavage, or (2) a misfolded structure which is more easily proteolyzed, or is
no longer capable of binding to or acting on a substrate.
5.2.3 In vitro studies of Arg-142-Cys
To find out whether the result of the Arg-142-Cys mutation is a rapid proteolytic cleavage or an
otherwise altered structure, the homology between TGM1 and FXIII was again utilized. The Arg-142-
Cys mutation was introduced into the corresponding site of the FXIII A-subunit cDNA, and the
consequences of the mutation on the structurally homologous factor XIII A-subunit were studied in
vitro in a COS cell expression system (Study I). The mutant protein accumulated in the cells in reduced
quantities compared to the wild type protein, as analyzed by immunoblotting of the transfected cell
homogenates. In pulse chase experiments, the mutant protein demonstrated marked instability and
almost complete degradation within 24 hours. Thus, on the basis of structural homology of the FXIII
and TGase 1 enzymes and conservation of the polypeptide sequence around the mutation, it is highly
likely that instability and susceptibility to proteolytic degradation is at least one of the consequences of
the Arg-142-Cys mutation. The corresponding mutation in FXIII was also devoid of TGase activity.
However, although models of Arg-142-Cys in FXIII seem to result in rapid protein degradation, TGase
1 and FXIII have some distinct characteristics, and in vivo totally different functions. Moreover, the
biology of TGase 1 has revealed more complexity than was predicted at the start of our study. These
aspects restrict the conclusions that can be drawn from our data.
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Figure 10. Stereoviews of the modeled Arg-142-Cys mutation site. The beta sandwich and
catalytic core domains are shown as light and dark colored coil structures, respectively. The
side-chain moieties of the two conserved Arg 141 and Arg 142 residues in the sandwich
domain are shown as ball-and-stick structures. These two residues participate in a number of
hydrogen-bonding interactions which stabilize sandwich loop conformations and, more
importantly, tether the sandwich domain to the catalytic core. The Arg 142 side-chain forms a
salt bridge with the conserved core residue Asp 253, and hydrogen-bonds with three main-
chain carbonyl groups. All of these interactions will be abolished in the Arg-142-Cys mutant
(side-chain shown in dark-colored ball-and-stick). The side-chain group of Asp 253, as well as
the carbonyl groups involved in hydrogen-bonding interactions with Arg 141 and Arg 142, are
shown as labeled ball-and-stick (Courtesy from Dr. Vivien Yee, Cleveland Clinic Foundation,
Ohio).
Other groups have also studied the Arg-142 region in vitro. Expression studies of the mutants Arg-141-
His, Arg-141-Cys, and Arg-142-His in TGase 1 by baculovirus/insect cell systems revealed reduced
enzymatic activities as expected (Candi et al. 1998). Expression levels and half-times of mutants were
comparable to those of the wild type in Western blot, but specific pulse chase experiments were not
performed. In addition, the baculovirus system is not able to process TGase 1 to its most active form.
As it is not a mammalian expression system, the post-translational modifications differ from
mammalian cells, therefore challenging the interpretation of the results. Expression of Arg-141-His in
normal human keratinocytes in the presence of both low and high calcium also demonstrated reduced
activity, but its stability was not examined (Candi et al. 1998).
5.2.4 Characterization of other mutants – Gly-217-Ser, Val-378-Leu, Arg-395-Leu, and 3339A-
to-G
We utilized the homology model of TGase 1 also in mutational modeling of other identified mutations
(Study I). Gly217 residue is located far from the active site (>20 Å). In the FXIII A-subunit structure,
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the conserved sandwich Gly217 residue is located at the end of the β-strand near the core domain
interface and has a main chain conformation which is unfavorable for other amino acids with their
larger side-chain groups that introduce short steric contacts. Based on this model, the Gly-217-Ser
mutation results in altered protein folding which can affect protein stability or function.
The conserved core Val378 residue is located in the active site helix, two amino acids downstream
from the catalytic Cys376 residue. The Val378 side chain is buried in a pocket formed by conserved
hydrophobic residues. Substitution of the larger leucine side-chain introduces unfavorable contacts
which are likely to result in a limited local conformational change in the structure. These changes are
likely to extend to the catalytic residues and can drastically affect the catalytic behavior of the mutant
molecule.
Arg-385-Leu affects a conserved core residue which is at one end of a conserved string of hydrogen-
bonding interactions (Arg395-Asp439-Tyr543-Trp437 in TGM 1; Arg333-Glu377-Tyr481-Trp375 in
the FXIII A-subunit) which span the body of the core domain. The substitution of a hydrophobic
leucine side-chain for the positively charged Arg395 disrupts the conserved hydrogen-bonding pattern
and creates electrostatic conflicts, yielding a mutant protein with altered structure which extends to the
active site, or which is more unstable or easily degraded.
We did not study any consequences of the 3339 A to G mutation in our one patient, but previous
studies exists on this mutation. In Norwegian patients, 3339A to G results in an insertion of one
intronic G into the mRNA because of the A to G point mutation in the acceptor splice site of intron 5
(Pigg et al. 1998). This mutation leads to a frameshift and premature termination at codon 3345. In
Norway, this mutation is present in 80% of disease alleles, suggesting a single founder mutation in the
majority of patients. The mutation has also been found in Swiss patients, but with different
consequences (Huber et al. 1995). The mutation leads to a retention of intron 5 sequence in mRNA,
resulting in a premature stop codon. No detailed studies exist on the precise consequences of this
mutation, but it could lead to 1) reduced levels of mRNA due to nonsense mediated mRNA decay, 2)
several variants of differently spliced mRNA transcripts, which has been reported with splice site
mutations, or 3) a truncated protein, which is unable to function properly because it lacks the catalytic
site. It has been shown, however, that the result of this mutation is lowered TGase activity (Huber et al.
1995).
5.3 GENOTYPE-PHENOTYPE CORRELATION OF ARCI
5.3.1 Clinical phenotypes of ARCI patients with TGM 1 mutations
After the detection of TGM 1 mutations, we compared the genotype data with clinical findings (study
II), showing that, the majority of 13 families (8, 62%) with TGM 1 mutations had a phenotype of
classic LI. However, the milder phenotype of patients in 5 families (38%) was also associated with
TGM 1 mutations. All of the patients with TGM 1 mutations were quite severely affected, and none of
them had the minimal white scaling described in some ichthyosis patients. The clinical presentation
between affected family members was relatively homogeneous. In addition, in some patients with
severe classic LI, mutations were not detected in screening. It should be noted that the sensitivity of our
screening method SSCP is only 60-80%, meaning that some of the mutations may have remained
undetected.
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In most mutation reports, the phenotype of affected individuals has been a severe form of LI with a
brown, platelike scale (Hennies et al. 1998; Russell et al. 1994). In some studies, however, a CIE
phenotype has also been reported. In a Norwegian sample of 34 ARCI patients with TGM 1 mutations,
30 LI patients (88%) and 4 CIE patients (12%) were found (Pigg et al. 1998). Furthermore, in a German
study of 9 families, 3 of 9 patients had clinical CIE, 1 patient was mildly affected with minimal scaling,
and the rest of the patients presented with the classic LI phenotype (Hennies et al. 1998). Some authors,
however, have been skeptical as to whether CIE can be caused by mutations in TGM 1 (Shevchenko et
al. 2000). In one study, TGM 1 mutations had been excluded from 5 CIE patients, although an
abnormal cytoplasmic TGase 1 expression pattern and intermediate enzyme activity were observed in
those patients (Choate et al. 1998). Although the defect in these patients was not due to alterations in
the TGM 1 gene, the abnormal focal expression of TGase 1 may result in a pathogenic disruption in
epidermal differentiation as well.
Although TGM 1 is expressed in some extracutaneous stratified epithelia such as intestinal and tracheal
epithelia, ARCI is considered purely a disease of the epidermis and its appendages. Some authors have
speculated that this may be due to the suggested role of TGase 1 in assembling both the lipid envelope
by esterbond formation and the protein envelope by cross-linking CE proteins in the skin (Nemes et al.
1999). Other epithelial tissues also forms envelopes, but the lipid envelope is a unique feature in the
skin. Therefore, the defective TGase 1 can possibly cause severe manifestations specifically in skin.
5.3.2 Morphological findings in patients with TGM 1 mutations
Ultrastructurally, all of our TGM 1 patients belonged to either IC type I or type II (Study II). All of the
IC type II patients and a third of the IC type I patients harbored TGM 1 mutations. Ultrastructural
diagnosis of ARCI has been controversial, but it does seem to detect ARCI patients with TGM 1
mutations to some extent. Besides ours, only one other study has been published in which the affected
patients were classified ultrastructurally (Pigg et al. 1998). In that Norwegian study, only two of 34
patients with TGM 1 mutations were classified as IC type I, whereas 32 patients has the type II disease.
None of the ARCI patients with TGM 1 mutations has belonged to ARCI types III and IV in any study.
5.3.3 TGM 1 mutations and phenotype
Among 13 families with TGM 1 mutations, most of the affected individuals were compound
heterozygotes; only two patients were homozygotes. We found no correlation between the type of the
TGM 1 mutation and phenotype of the ARCI patients (Study II). Five different mutation combinations
were shown to cause type II ichthyosis, which is a clinically homogeneous group. Interestingly, the
same mutations were also characterized in patients with type I ichthyosis. Furthermore, two patients,
who both carried the mutation combination Arg-142-Cys/Val-378-Leu, had different clinical pictures
and different ultrastructural findings. Similar observations were demonstrated in the German study in
which patients homozygous for the splicesite mutation 3339 A to G showed differences in their clinical
pictures (Hennies et al. 1998). Furthermore, 3 Norwegian CIE patients and 30 LI patients were all
homozygous for the same 3339 A to G mutation (Pigg et al. 1998).
5.3.4 Locus heterogeneity and the phenotype
The genetic heterogeneity of ARCI is well-established, and five different loci have been linked to the
disease. Variable figures have been achieved on the proportion of ARCI patients associated with the
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TGM 1 gene defect. In this study, 13 of 38 ARCI families (34%) showed linkes with TGM 1 mutations
(Study II). An almost similar distribution was achieved in a recent linkage study performed by a French
group, involving a collection of 51 consanguineous families originating from North Africa, Turkey, and
France. In this sample, 11 families (22%) were linked to the chromosome 14 (TGM 1) locus (Fischer et
al. 2000). Based on biochemical observations utilizing TGase 1 activity measurements and
immunofluorescence studies, 50% of ARCI patients have been associated with the TGM 1 gene defect
(Hohl et al. 1997). In 43 Norwegian families, 34 (80%) were found to carry a single founder TGM 1
mutation (Pigg et al. 1998). Variations in these figures may reflect differences in diagnostic criteria
and/or differences in genetic disease profiles between different ethnic backgrounds.
Only the French study described above includes investigation of loci other than TGM 1 (Fischer et al.
2000). In that study of 51 ARCI families, 17 families (34%) were linked to other chromosomal loci on
chromosome 2 (5 families, 10%), chromosome 19 (6 families, 12%), and chromosome 3 (6 families,
12%). In addition, 23 families (45%) were excluded from these loci, indicating the presence of at least
one additional locus for ARCI, if not more. In that study, the patients linked to chromosome 3 clinically
resembled CIE, whereas the patients linked to chromosome 19 have a classical LI phenotype. The
phenotype in these families was reported to be more homogeneous than that in a group with TGM 1
mutations. Patients of the Larsmo family, linked to chromosome 19, had an clearly milder phenotype
with only minimal scaling compared with chromosome 19-linked patients in the French study (Study
III). It remains, however, possible that the locus of Larsmo family represents a separate entity from that
of French families. The chromosome 19 region demonstrating linkage was somewhat more broad and
more proximal in the French study (19p12-q12) than in our study (19p13.1.-13.2.). In a German study,
comparison of six patients excluded from TGM1 with those linked to TGM 1 did not reveal any
specific clinical features which could separate these groups from each other (Hennies et al. 1998). Both
showed an entire spectrum of clinical features of ARCI from erythrodermic fine scaling to non-
erythrodermic, large, dark scales.
Among inherited diseases, locus heterogeneity seems to be a rather common phenomenon. It is often
found in syndromes that result from failure of rather general pathways involving many genes (Strachan
and Read 1996). Such complex pathways are for example, vision and hearing. A defect in any of the
genes of the same pathway may lead to similar clinical results. A striking example is Usher syndrome,
an autosomal recessive combination of hearing loss and retinitis pigmentosa, where at least 8 loci have
been found on chromosomes 1, 3, 10, 11, and 14 in three different clinical forms (Chaib et al. 1997;
Hmani et al. 1999; Kaplan et al. 1992; Kimberling et al. 1992; Kimberling et al. 1990; Sankila et al.
1995; Smith et al. 1992; Wayne et al. 1996). Moreover, defects in genes coding for a different part of a
same structural unit can cause similar clinical phenotypes. A good example is epidermolysis bullosa, in
which defects in at least 10 genes coding for different basement membrane zone proteins result in
bullous disease with a rather similar outcome. The locus heterogeneity of ARCI seems to be significant.
Although only one gene in the ARCI is known so far, it may be that some of the other ARCI loci reveal
genes involved in the formation or function of CE, which is quite a complex structure itself, or reveal
genes that disturb the normal function of TGase 1.
5.3.5 Challenges in phenotype evaluation
The evaluation of genotype-phenotype correlations in ARCI is challenging for many reasons. Diagnosis
of ARCI is based on its clinical presentation and histology, and unfortunately, no more objective
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diagnostic methods, such as laboratory tests, are available. This makes the diagnosis dependent on the
subjective judgments of the dermatologist and the pathologist. Furthermore, local medical practice may
create differences in diagnostics. Clinical differentiation of LI and CIE is not straightforward and there
are intermediate forms of ARCI that are difficult to place in either of these entities. Some of the clinical
features, such as erythrodermia, appers and disappears. Retinoid therapy and the patient’s own activity
in treating the disease with emollients affects clinical features. This further complicates the evaluation
of the phenotype. In addition, different criteria used for ARCI classifications confuse the correlation of
different genotype-phenotype studies with each other. The final evaluation of phenotype-genotype
correlations of ARCI will be accomplished only when more of the underlying genes have been
characterized, and meaningful genotype-phenotype correlations are possible.
5.3.6 Clinical and morphological findings in a subgroup of ARCI
During evaluation of genotype-phenotype correlations among patients with TGM 1 mutations, we
found a subgroup of ARCI patients with rather uniform electron-microscopic findings (Study IV). In
that subgroup the morphological findings, abnormal keratohyalin and keratinosomes, resemble those
described earlier only in harlequin ichthyosis patients. We demonstrated that similar ultrastructural
findings can be detected in ARCI patients lacking the harlequin ichthyosis phenotype. The clinical
picture of these patients was more variable than were their findings in electron microscopy, although
some clinical features, such as accentuation of ichthyosis in the scalp, large and thick scales,
erythrodermia, ectropion, and alopecia were common features of nearly all patients. A peculiar
malformation of digits and toes exists in some of the patients. In this subgroup of ARCI patients TGM
1 mutations were excluded.
5.4 ASSIGNMENT OF THE NEW ARCI LOCUS ON CHROMOSOME 19P13.1.-13.2.
As TGM 1 was revealed to be the defective gene in only a third of the ARCI families, we decided to
search for other defective genes in ARCI (Study III). Due to the genetic and clinical heterogeneity of
ARCI, we decided to focus on consanguineous families in order to identify new genes for ARCI.
Among the families not associated with a TGM 1 gene defect, one large IC type I family originating
from the genetically isolated island of Larsmo existed (Figure 11A). Close consanguinity could be
observed in the Larsmo pedigree. The parents of patient 5 were second cousins, and the mother of
patient 5, the father of patients 6 and 7 and the mother of patient 9 shared a common grandparent, as
did the mother of patients 6 to 8 and the father of patient 9. Due to this consanguinity, a homozygosity
mapping strategy was applied to search for a new gene locus. In homozygosity mapping, affected
members of the family are expected to be homozygous for the disease-causing allele, and the whole
segment of the chromosome flanking the disease locus is predicted to be identical by descent. A
conservative prediction was that patient 5 should be homozygous for one mutant allele and this same
mutant allele should be at least one of the disease alleles in patients 6 to 9. Patients 6 to 9 should also
share another mutant allele. Based on the hypothesis of one ancestral founder mutation in a genetically
isolated population, we assumed that only one mutant allele should be found in this pedigree.
Prior to initiating the genotyping, data simulation analysis was carried out to determine whether
conclusive results could be achieved from linkage analysis of the chosen family. This simulation
analysis revealed a maximum expected LOD score of 3.57 and mean expected LOD score of 1.36 at
recombination fraction (θ) = 0.010. Therefore, an evenly spread set of informative markers could be
expected to yield a conclusive LOD score in the family material.
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5.4.1 Exclusion of candidate loci
First we selected 5 possible chromosomal loci, the TGM 2 and 3 loci on 20q11.2, Keratin (KRT) loci in
17q and 12q11-q13, a second locus for ARCI on 2q33-q35, and the epidermal differentiation complex
on 1q. TGase 2 and 3 are expressed in keratinocytes, and TGase 3, as well as genes in the epidermal
differentiation complex, take part in CE formation, which make these loci interesting candidate regions.
Keratins are shown to be defective in many genodermatoses and were included in the candidate loci
analysis. Linkage for the ARCI gene to these candidate loci could be excluded since LOD scores below
-2.0 were detected with every marker flanking these loci.
5.4.2 Genome scan
After the candidate loci analysis, we performed a genome-wide scan using 370 polymorphic markers
spaced at about 10 cM distances and analyzing five affected individuals as well as their parents, in total
nine samples. None of the initial markers revealed homozygosity between the affected individuals, but
the two-point linkage analysis revealed two interesting regions, one on chromosome 9 (D9S158 LOD
score 2.05) and another on chromosome 19 (D19S432 LOD score 2.28 ). The chromosome 9 area was
excluded as a disease locus by analysis of the haplotypes formed by four additional microsatellite
markers around the area of interest (data not shown). In contrast, when 11 additional microsatellite
markers were analyzed from the chromosomal region 19p13.1-p13.2, they revealed a region of about
6.0 cM where all markers produced strong positive LOD scores (Figure 11B). In the final calculations,
the allele frequencies from Larsmo population were used.
Haplotypes consisting of 14 microsatellite markers flanking the chromosome 19 region restricted the
disease locus spanning about 6 cM between markers D19S411 and D19S914 on 19p13.1-13.2 (Figure
11A). Two alleles were identified in the disease chromosomes, with most of the markers revealing two
core haplotypes (Figure 11 A). Two adjacent loci in the middle of the haplotype, D19S415 and
D19S179, revealed homozygosity in all affected individuals. However, these alleles were found to be
quite common among the Larsmo population, and the heterozygosity of the markers was low. The
significance of this finding of homozygosity thus remains to be studied further and cannot yet be
considered conclusive evidence for a shared chromosomal region among all affected individuals.
A French group has also published linkage on chromosome 19p12-q12 based a genome scan of nine
consanguineous, severely affected LI families (Fischer et al. 2000). However, according to the LLNL
physical map and the Genethon genetic map, these regions do not overlap, but have 2 cM between
them. The possibility exists that these regions represent two separate ARCI loci, which is supported by
the fact that phenotypes of our family and the nine French families differ from each other. Yet, errors
still exist in published maps, and heterogeneity of ARCI patients is common, making it equally possible
that these regions do overlap and represent only one ARCI locus on 19p.
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Figure 11
A) Pedigree and haplotypes of the ARCI family on chromosome 19. Persons marked with * were
included in the genome scan. Recombinations in patient 9 restricted the area between D19S914
and D19S411.
B) Linkage of the ARCI family to chromosome 19p13.1.-13.2. Cloned genes and some of the loci
on the linkage region are shown in the middle. LOD scores to the loci are presented on the right.
GCDH=Glutaryl CoA dehydrogenase, CALR=calreticulin, RAD23A=?, NFIX =nuclear factor I,
X-type, LYL 1=lymphoid leukemia 1, CACNA 1A4= voltage-dependent Ca2+ channel,
RFX 1=regulatory factor 1, OLFR =olfactory receptor, CD97 =cluster of differentiation, 97,
SLC1A6R=solute carrier family 1 A, member 6, CYP4E3=cytocrome P450 4F2
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5.4.3 The new ARCI locus on chromosome 19
The new ARCI locus is localized at a region where significant progress has been made in the human
genome sequencing project. According to the LLNL, which is the major sequencing center for of
chromosome 19, the new ARCI locus is located on a 3.0 Mb area of which 1.34 Mb has been
sequenced. Chromosome 19 is one of the most gene-rich chromosomes. Thirteen known genes and 65
ESTs have been localized to the ARCI critical interval (Ashworth et al. 1995). There are several
possible candidate genes, including CACNA1A, a voltage-dependent Ca2+ channel gene (Diriong et al.
1995), calreticulin, a major calcium storage protein in the lumen of the endoplasmic reticulum
(McCauliffe et al. 1990), and SLC1A6, solute carrier family 1 member 6, an amino acid transporter
regulating the level of extracellular glutamate (Figure 11B) (Fairman et al. 1995). Calcium is an
important regulator of epidermal differentiation as has been described. Although CACNA1A has been
previously shown to associate with three neurological diseases (familial hemiplegic migraine, episodic
ataxia type 2, and spinocerebellar ataxia type 6) (Ophoff et al. 1996; Zhuchenko et al. 1997), and its
expression in keratinocytes is ambiguous, it remains, along with calreticulin, an interesting candidate
gene for ichthyosis. The functions of SLC1A6 or EAAT4 (excitatory amino acid transporter) associated
with the glutamate signaling pathway has mainly been studied in neurons, but recent progress shows
that the glutamate signaling pathway is also present in the skin, making SLC1A6 an interesting
candidate gene (Maxfield et al. 1999).
One efficient way to search for candidate genes is to compare the human transcript map to maps of
other species, for example the mouse. Mouse homologies of genes located on 19p are widely dispersed
in the mouse genome. At least 5 distinct homology segments exist in mouse chromosomes 8, 9, 10, and
17. However, although most of our new ARCI locus on chromosome 19p13.1-13.2 seems to map on
mouse chromosome 8 (MMU 8), the man-mouse homology relationship in this region is suggested to
be complex, and it is difficult to predict whether homologies of mouse genes in that region should map
to 19p in human beings (Mohrenweiser et al. 1996).
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6 SUMMARY AND CONCLUSIONS
Autosomal recessive congenital ichthyosis (ARCI) is a clinically and genetically heterogeneous group
of genodermatoses which typically result in a severe scaling disease of the skin. Substantial progress
has been made in the study of the pathogenesis of ARCI in recent years. In 1995, the transglutaminase 1
gene (TGM 1) was revealed to have mutations in a subgroup of ARCI patients. The function of TGM 1
is to catalyze the formation of the cornified cell envelope, a tightly cross-linked network of proteins
formed in the upper keratinocytes of the skin, in the later stages of epidermal differentiation.
The aim of this study was to further clarify the molecular mechanisms underlying ARCI. Fifty Finnish
ARCI patients exist, who prior to this study were ultrastructurally classified into four distinct groups. In
the first stage, TGM 1 mutations were screened in these patients. Six different mutations were found in
one third of the patients. Five of the mutations were point mutations causing amino acid substitutions.
In addition, one splice site mutation was detected. Mutational modeling utilizing the three-dimensional
structure of a homologous transglutaminase, coagulation factor XIII, showed that mutations were
located in conserved regions of the protein and were likely to cause structural alterations and ultimately
the disease. One of these mutations, Arg-142-Cys, was found to be mutated twice in Finnish patients
and to be located in a mutation-prone area. Due to these interesting features, we studied the mutation
more thoroughly by in vitro studies and demonstrated that the mutated protein is rapidly degraded in
cells.
The genotype-phenotype correlation studies implied that 62% of those patients with the TGM 1
mutations were severely affected classical lamellar ichthyosis patients belonging to ultrastructural
group type II, and 32% were mildly affected and belonged to ultrastructural group type I. Surprisingly,
the same mutations were shown to result in both ultrastructural types I and II, and furthermore, no clear
causative relationship between the phenotype and mutation type was observed. We also reported a
subgroup of ARCI patients with ultrastructural findings resembling those of harlequin ichthyosis, but
without the harlequin ichthyosis phenotype.
Since the TGM 1 gene defects explained only one third of ARCI cases, we decided to search for a new
ARCI gene. A primary random search of the human genome was performed in one large
consanguineous family with five affected patients originating from a genetic subisolate, the archipelago
of Larsmo. This genome scan resulted in assignment of a new ARCI locus on chromosome 19p13.1.-
13.2. Two core haplotypes were identified from a pedigree restricting the region to 6 cM. The ARCI
gene remains to be identified within a region containing several possible candidate genes.
This study clarifies in part the molecular mechanisms behind autosomal recessive congenital ichthyosis.
TGM 1 mutations and the genotype-phenotype correlation of ARCI and TGM 1 were characterized in
Finnish patients. Due to the lack of a clear founder mutation for TGM 1 in Finland, DNA-based
diagnostics is only partially feasible in Finland. In addition to detection of TGM 1 mutations, we
localized a new locus for an additional ARCI gene on chromosome 19p13.1.-13.2 and provided a
stepping stone for the cloning of a new ARCI gene. Further studies on the molecular mechanisms of
this rare disease are needed to clarify its basic pathogenic mechanisms. These studies may offer new
understanding of the molecules essential for the normal function of the skin.
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